

SUBJECT INDEX

- 1000 genomes 19-OR, 1770-P
 12-Lipoxygenase 59-OR, 2929-PO
 3D microenvironment 2308-P
 ABC control 260-OR
 Abdominal obesity 827-P
 Abnormal glucose tolerance 1566-P
 Abnormal haemoglobin 2728-PO
 Acanthosis nigricans 2906-PO
 Acarbose insulin therapy 970-P
 ACC 2037-P
 Accidents 401-P
 Accountable care organizations 1331-P
 Acculturation 755-P
 Accuracy 946-P
 Acetyl-CoA inhibition 1280-P
 Acromegaly 2883-PO
 AcSDKP 548-P
 Activating transcription factor 4 670-P
 Activity 730-P
 Activity monitors 809-P
 Acute coronary syndrome 510-P, 2688-PO
 Acute diabetes complications 1682-P
 Acute exercise 295-OR
 Acute kidney injury 587-P, 1640-P
 Acute meal challenge 2014-P
 Acute pancreatitis 1703-P
 Adenovirus transduction 2358-P
 Adherence 433-P, 871-P, 887-P, 899-P, 900-P, 1125-P, 1144-P, 1192-P, 1411-P, 2519-PO, 2629-PO
 Adipocyte 33-OR, 34-OR, 37-OR, 330-OR, 1853-P, 1896-P, 2144-P, 2153-P, 2243-P, 2818-PO
 Adipocyte differentiation 1868-P, 2166-P
 Adipocyte endoplasmic reticulum 1865-P
 Adipocyte fatty acid binding protein 511-P
 Adipocyte regeneration 321-OR
 Adipocytokines 1708-P
 Adipogenesis 36-OR, 366-OR, 1848-P, 1851-P, 1867-P, 2120-P, 2125-P, 2131-P, 2155-P, 2884-PO
 Adipokines 629-P, 1463-P, 2096-P, 2053-P
 Adiponectin 315-OR, 679-P, 1219-P, 1243-P, 1602-P, 1866-P, 1873-P, 1876-P, 1977-P, 2031-P, 2072-P, 2253-P, 2313-P
 Adipose progenitors 333-OR
 Adipose specific insulin resistance 321-OR
 Adipose stem cells 163-OR
 Adipose tissue 35-OR, 117-OR, 118-OR, 335-OR, 1852-P, 1858-P, 2004-P, 2075-P, 2182-P, 2197-P, 2204-P
 Adipose tissue expansion 333-OR
 Adipose tissue fatty acid composition 1869-P
 Adipose tissue fibrosis 1861-P
 Adipose tissue function 60-OR
 Adolescents 67-OR, 862-P, 898-P, 1400-P, 1406-P, 1415-P, 1702-P, 1714-P, 2719-PO, 2648-PO, 2895-PO
 Adrenomedullin 2266-P
 Adults 1064-P
 Advanced glycation end products 68-OR, 486-P, 491-P, 597-P, 625-P, 1734-P, 2447-PO
 Aerobic exercise 794-P, 813-P, 2394-PO
 Aerosol 1028-P
 Aetyl-CoA carboxylase 1288-P
 AFF3 1751-P
 Afferent arteriolar resistance 579-P
 Affordable Care Act 209-OR
 Africa 1771-P
 African American 204-OR, 311-OR, 896-P, 1758-P
 AGE 656-P, 1412-P
 Aged 1671-P
 Age-related macular degeneration 2447-PO
 AGEs 589-P
 Aging 799-P, 1006-P, 1482-P, 1487-P, 1662-P, 2027-P
 Aging surface markers 2334-P
 Albiglutide 1130-P, 1153-P, 2558-PO, 2570-PO
 Albumin creatinine ratio 611-P
 Albuminuria 456-P, 583-P, 2621-PO, 2687-PO
 Alcohol 1624-P
 Alcohol and marijuana use 1714-P
 Alexithymia 910-P
 Allogeneic bone marrow 2308-P
 Alogliptin 13-OR, 2579-PO
 Alpha cell 2302-P
 Alpha-2 adrenergic receptor 1308-P
 Alternative splicing 2234-P, 2305-P
 Altitude 1635-P
 Alubuminuria 925-P
 Alzheimer's disease 1309-P, 2442-PO
 Ambulatory blood pressure monitoring 1146-P
 American Indians 1614-P
 Amino acids 1993-P, 2216-P, 2364-P
 Amish 1763-P
 AMP-activated protein kinase 125-OR, 126-OR, 566-P, 1861-P, 1900-P, 1987-P, 2039-P, 2104-P, 2484-PO
 Amputation 143-OR, 732-P
 Amylin 1101-P, 2160-P
 Amylin analogue 1098-P
 Amyloid 1039-P, 2270-P
 Anakinra 188-OR
 Anaplerosis 345-OR
 Anesthesia 1308-P
 Angiogenesis 198-OR, 437-P, 1882-P, 2028-P
 Angiotensin-like protein 4 476-P, 505-P
 Angiotensin 567-P
 ANGPTL8 2834-PO
 Anthropometric index 508-P
 Anthropometric predictors 1543-P
 Antibiotic sensitivity 2731-PO
 Antibodies 1135-P, 1811-P
 Anti-diabetic action 255-OR
 Anti-diabetic effect 2615-PO
 Anti-diabetic treatment 1315-P
 Anti-hyperglycemia effect 839-P
 Anti-hyperglycemic agents 1143-P, 2588-PO, 2602-PO
 Anti-hypertensives 2427-PO
 Anti-IL-7R α antibodies 27-OR
 Anti-inflammatory 1242-P, 1310-P
 Anti-insulin glargine antibodies 1029-P
 Anti-mullerian hormone 1479-P
 Anti-oxidant effect 1214-P
 Anti-oxidant 1427-P
 Anti-vascular endothelial growth factor 290-OR
 Anxiety 217-OR, 861-P, 1871-P
 Aortic aneurysm 434-P
 Aortic blood pressure 1518-P
 Apelin 2080-P
 aPKC 1923-P
 Apolipoprotein B 2190-P
 Apolipoprotein C-III 253-OR, 692-P
 Apolipoprotein J 1979-P, 2116-P
 Apolipoprotein L1 1797-P
 Apolipoprotein M 710-P
 Apoptosis 2257-P, 2272-P, 2283-P, 2827-PO
 Appetite 2103-P, 2114-P
 APPL2 1873-P
 Arterial stiffness 449-P, 476-P, 479-P, 496-P, 699-P, 1172-P, 1511-P, 2406-PO, 2165-P
 Arterial velocity pulse Index 2395-PO
 Arteriogenesis 529-P
 Arteriolar hyalinosis predicts 583-P
 Artificial pancreas 222-OR, 223-OR, 224-OR, 225-OR, 383-OR, 417-P, 940-P, 953-P, 1059-P, 1066-P, 1074-P, 1076-P, 2524-PO, 2529-PO
 Arylhydrocarbon receptor binding 1529-P
 Asian 1175-P, 2584-PO
 Asian Indian 1553-P
 Aspart 983-P
 Aspirin 1594-P
 Assisted reproductive technology 2670-PO
 Astrocyte 404-P, 1871-P
 Astrocytic dysfunction 656-P
 Asymptomatic coronary artery stenosis 2396-PO
 Asymptomatic type 1 diabetes 359-OR
 Atherosclerosis 56-OR, 200-OR, 202-OR, 428-P, 441-P, 453-P, 454-P, 456-P, 471-P, 489-P, 517-P, 522-P, 530-P, 2395-PO, 2410-PO
 Atomoxetine 395-P, 396-P
 Atorvastatin 699-P
 ATP 2019-P, 2026-P
 Attributable risk 440-P
 Atypical antipsychotic 238-OR
 Auricular concha electroacupuncture 2432-PO
 Autoantibodies 217-OR, 1802-P, 1810-P, 2649-PO, 2806-PO
 Autoantigen 32-OR, 2784-PO
 Autoimmune diabetes 26-OR
 Autoimmunity 28-OR, 1419-P, 1820-P
 Autonomous neuropathy 2441-PO
 Autophagy 295-OR, 377-OR, 472-P, 532-P, 1854-P, 1862-P, 1886-P, 1980-P, 2254-P, 2267-P, 2268-P, 2275-P, 2279-P, 2409-PO, 2411-PO, 2650-PO
 Autophagy signaling 795-P
 Average daily risk range 943-P
 Bariatric surgery 67-OR, 241-OR, 596-P, 1970-P, 1994-P, 2138-P, 2156-P, 2176-P, 2183-P, 2204-P, 2208-P, 2215-P, 2226-P, 2846-PO, 2893-PO, 2898-PO, 2904-PO, 2905-PO, 2908-PO
 Barriers 761-P, 815-P, 2770-PO
 BAS 542-P
 Basal bolus insulin 1041-P, 1049-P, 2536-PO, 2762-PO
 Basal insulin 99-OR, 423-P, 606-P, 884-P, 995-P, 997-P, 999-P, 1015-P, 1037-P, 1038-P, 1079-P, 1090-P, 1156-P, 2528-PO
 Basal insulin peglispro 93-OR, 94-OR, 95-OR, 984-P, 985-P, 986-P, 989-P, 990-P, 993-P, 996-P, 998-P, 1004-P, 1018-P, 1025-P, 1032-P
 Basal insulin supported oral therapy 2759-PO, 2780-PO
 Baseline HbA1c 1277-P
 Basement membrane proteins 448-P
 BAT 292-OR
 BDNF 2064-P
 BeAM value 1036-P, 2539-PO
 Behavior change model 771-P
 Behavioral health 214-OR, 1289-P
 Behavioral intervention 856-P
 Behavioral 892-P

- Beige adipocyte 2025-P, 2197-P
 Berberine 2857-PO
 Berberis aristata 2483-PO
 Beta 2 adrenergic receptor 537-P
 Beta cell 130-OR, 132-OR, 244-OR, 339-OR, 1122-P, 1930-P, 2242-P, 2254-P, 2272-P, 2284-P, 2294-P, 2296-P, 2328-P, 2336-P, 2337-P, 2339-P, 2341-P, 2344-P, 2367-P, 2844-PO, 2924-PO
 Beta cell aging 2334-P
 Beta cell apoptosis 2260-P, 2278-P
 Beta cell death mechanisms 1832-P, 2276-P
 Beta cell dedifferentiation 2315-P
 Beta cell development 2297-P, 2305-P
 Beta cell differentiation 185-OR
 Beta cell dysfunction 1563-P, 1621-P
 Beta cell epithelial-mesenchymal transition 136-OR
 Beta cell failure 2267-P, 2319-P, 2326-P
 Beta cell function 357-OR, 812-P, 1155-P, 1936-P, 1939-P, 2096-P, 2371-P, 2918-PO, 2847-PO
 Beta cell identity 250-OR
 Beta cell mass 2298-P
 Beta cell performance 2922-PO
 Beta cell programming 2297-P
 Beta cell proliferation 248-OR, 341-OR
 Beta cell regeneration 2286-P, 2340-P
 Beta cell replication in age 378-OR, 2285-P
 Betatrophin 2067-P, 2187-P, 2355-P, 2674-PO, 2834-PO, 2916-PO, 2929-PO
 Bezafibrate 1834-P
 BGTS utilization 2641-PO
 BIABA 799-P
 BID switching 1021-P
 Bile acids 828-P, 1911-P, 2105-P
 Bilirubin 609-P
 Binding affinity 2551-PO
 Bioactive lipids 661-P
 Bioartificial pancreas 2814-PO
 Bioenergetics failure 342-OR, 2354-P
 Bioengineering 1838-P, 1842-P
 Bioimpedance 833-P
 Biological clock 2042-P, 2109-P
 Bioluminescent assay 1889-P
 Biomarker 63-OR, 135-OR, 184-OR, 229-OR, 232-OR, 274-OR, 361-OR, 648-P, 1526-P, 1596-P, 1609-P, 1669-P, 1811-P, 1887-P, 2276-P, 2398-PO
 Biometry 1436-P
 Bionic pancreas 222-OR
 Biosimilar Insulin 1023-P
 Birth weight 23-OR, 1698-P, 2035-P
 Bladder cystometry 635-P
 Blog 2651-PO
 Blood based artificial pancreas 2547-PO
 Blood brain barrier permeability 1840-P
 Blood glucose 961-P
 Blood glucose control 888-P
 Blood glucose monitoring system 430-P, 938-P, 946-P, 965-P, 2512-PO, 2715-PO
 Blood glucose variation 2549-PO
 Blood pressure 2891-PO
 Body composition 72-OR, 147-OR, 1456-P, 1644-P
 Body fat 2227-P
 Body fat distribution 2574-PO
 Body mass index 444-P, 805-P, 1507-P, 1699-P, 2554-PO, 2768-PO
 Boen metabolism 2797-PO
 Bolus calculator 1063-P, 1081-P
 Bone 165-OR, 2071-P
 Bone cells 2025-P
 Bone fractures 1613-P
 Bone marrow 284-OR, 329-OR, 707-P, 2901-PO
 Bone mineral density 272-OR, 2777-PO
 Brain blood flow 430-P
 Brain Inflammation 2106-P
 Brain microvasculature 1291-P, 1909-P
 Brain 5-OR, 45-OR, 160-OR, 351-OR, 356-OR, 403-P, 1891-P, 1964-P, 1990-P, 2822-PO, 2832-PO
 Branched hain amino acid metabolism 1311-P, 2248-P, 2904-PO
 Branching morphogenesis 2309-P
 Breakfast skipping 1992-P
 Breast cancer 1690-P
 Breast feeding 1381-P, 1460-P, 1467-P, 1618-P
 Brite adipocytes 1989-P
 Bromocriptine 1196-P
 Brown adipose tissue 116-OR, 119-OR, 120-OR, 121-OR, 2108-P, 2143-P, 2163-P
 Brown fat 2147-P
 Browning of white adipocytes 334-OR, 2148-P, 2887-PO
 Burden 1610-P
 Bydureon® 1138-P
 Bypass 2896-PO
 Calcium 2343-P, 2349-P
 Canagliflozin 1265-P, 1292-P, 2620-PO
 Cancer 11-OR, 322-OR, 1012-P, 1654-P, 1664-P, 1709-P, 1915-P, 2047-P, 2093-P, 2772-PO
 Capillary recruitment 2207-P
 Carbohydrate 2751-PO
 Carbohydrate metabolism 1843-P, 2100-P
 Carbohydrate responsive-element binding protein 1628-P, 1976-P, 2361-P, 2362-P
 Carbon monoxide 2282-P
 Cardiac autonomic function 447-P
 Cardiac autonomic neuropathy 621-P, 2443-PO
 Cardiac biomarkers 1629-P
 Cardiac function, diabetes 435-P
 Cardiac repolarization 347-OR
 Cardiometabolic risk 304-OR, 2194-P
 Cardiomyopathy 461-P
 Cardiopulmonary exercise test 2394-PO
 Cardiovascular 515-P, 520-P, 1517-P
 Cardiovascular autonomic imbalance 354-OR
 Cardiovascular autonomic neuropathy 588-P, 638-P, 640-P, 646-P, 2733-PO
 Cardiovascular complications diabetes 2162-P
 Cardiovascular death 2386-PO
 Cardiovascular disease 106-OR, 466-P, 468-P, 831-P, 1431-P, 1491-P, 1495-P, 1497-P, 1504-P, 2008-P, 2739-PO, 2693-PO
 Cardiovascular endpoints 2691-PO
 Cardiovascular events 13-OR, 440-P, 473-P, 481-P, 499-P, 516-P, 1489-P
 Cardiovascular mortality 1788-P, 2172-P
 Cardiovascular outcomes 455-P, 504-P, 611-P, 929-P, 1201-P
 Cardiovascular procedures 2735-PO
 Cardiovascular risk 9-OR, 58-OR, 446-P, 497-P, 814-P, 1388-P, 1459-P, 1492-P, 1501-P, 1513-P, 1514-P, 1603-P, 1650-P, 2643-PO, 2694-PO, 2699-PO
 Care coordination 1289-P
 Care delivery redesign 303-OR
 Care management 301-OR
 Care quality factors 1379-P
 Carnitine palmitoyltransferase 1 1982-P
 Carnitine 2002-P
 Carnosine 517-P
 Carotid atherosclerosis 506-P
 Carotid intima-media thickness 427-P, 495-P, 2402-PO
 Carotid stiffness 2902-PO
 Carpal tunnel syndrome 633-P
 Catalase 2134-P
 Catecholamine 2714-PO
 Caveolae 38-OR
 Cb1 antagonist 1864-P
 Celiac disease 70-OR
 Celiac disease autoimmunity 272-OR
 Celiac disease screening 895-P
 Cell cycle 2312-P
 Cell energy 1877-P
 Cell matrix protein 2830-PO
 Cell signaling 2856-PO
 Cell transplantation 185-OR
 Cellular adhesion molecule 1 2351-P
 Cellular therapy 1314-P
 Central adiposity 2202-P
 Central blood pressure 1518-P
 Central nervous system 159-OR
 Central obesity 1727-P
 Central regulation of metabolism 46-OR
 Ceramide 294-OR
 Cerebral blood flow 637-P
 Cerebral microvasculature 631-P
 Cerebral venous oxygenation 641-P
 Cesarean section 1721-P
 C-Fos 2169-P
 Chalcone 1310-P
 Charcot foot 719-P
 Charcot neuroarthropathy 2457-PO
 Checklist 758-P
 Chemerin 473-P, 2878-PO
 Chemokine CCR-2 580-P
 Childhood complications 632-P
 Childhood diabetes 1556-P
 Childhood obesity 22-OR, 69-OR, 146-OR, 1385-P, 1394-P, 2171-P, 2172-P
 China's elderly 1486-P
 Chinese 2462-PO
 Chinese Americans 2464-PO
 Chinese patients 1044-P
 Chitinase-3-like protein 1 43-OR
 Cholesterol 524-P, 691-P, 1990-P
 Cholesterol efflux 564-P
 Cholesterol guideline 1550-P
 Cholesterol lowering medication 694-P
 Chornobyl nuclear power plant 2765-PO
 Chromatin remodeling 325-OR
 Chromatin 324-OR
 Chronic inflammation 2137-P
 Chronic kidney disease 539-P, 588-P, 599-P, 1478-P, 1695-P, 2359-P, 2596-PO, 2687-PO
 Chronic liver disease 1593-P
 Chronic pancreatitis-related diabetes 136-OR
 Chronic periodontitis 2745-PO
 Chronic renal disease 586-P
 Chylomicron 256-OR
 Chylomicronemia 2530-PO
 Cigarette smoking 1578-P
 cIMT 1128-P
 Circadian clock 244-OR, 371-OR
 Circadian genes 2218-P
 Circadian protein 1969-P
 Circadian rhythm 1966-P, 2079-P
 CITED2 1882-P
 CKD3 81-OR
 Claims database 1686-P
 Clearance 1925-P
 Clinical characteristics 1705-P

- Clinical decision support software 304-OR
 Clinical decision support 1340-P, 2643-PO
 Clinical follow-up 1399-P
 Clinical inertia 208-OR, 1478-P
 Clinical trial 988-P
 CLOCK genes 1933-P
 Closed-loop 219-OR, 223-OR, 224-OR, 225-OR, 1066-P, 1078-P, 1131-P, 1841-P
 Closed-loop insulin delivery 221-OR, 1080-P
 Cockayne syndrome 1261-P
 Coefficient of variation 2488-PO
 Cognition 140-OR, 1579-P
 Cognitive abilities 1415-P, 2491-PO
 Cognitive dysfunction 1481-P
 Cognitive function 1451-P
 Cognitive impairment 637-P, 649-P
 Cognitive performance 2873-PO
 Cohort study 1630-P, 2751-PO
 Cold shipping study 2281-P
 Colesevelam 1238-P
 Collaborative care model 203-OR
 Collagen 2053-P
 Collection feasibility 878-P
 College students 786-P
 Combat sports 777-P
 Combination 1259-P, 2594-PO
 Combination therapy 2619-PO
 Combination treatment 10-OR
 Communal coping 859-P
 Community health workers 760-P, 762-P
 Community outreach program 916-P
 Community outreach 765-P
 Comorbid hypertension 1519-P
 Compartmental modeling 1799-P
 Compliance 1607-P, 2506-PO
 Complications 271-OR, 904-P, 1582-P
 Computational biology 536-P
 Concentrated Insulin 977-P, 2531-PO
 Conflict perceptions 913-P
 Congenital hyperinsulinism of infancy 2345-P
 Conjoint 206-OR
 Connexin36 gap junction coupling 2363-P
 Contamination 951-P
 Continuous glucagon receptor activation 129-OR
 Continuous glucose monitoring 167-OR, 170-OR, 178-OR, 180-OR, 181-OR, 757-P, 772-P, 790-P, 881-P, 934-P, 942-P, 947-P, 948-P, 949-P, 950-P, 954-P, 955-P, 960-P, 966-P, 967-P, 968-P, 969-P, 1110-P, 1139-P, 1241-P, 1411-P, 2511-PO, 2524-PO, 2534-PO
 Continuous glucose sensor 175-OR, 179-OR
 Continuous subcutaneous insulin infusion sets 226-OR, 994-P, 1005-P, 1010-P, 1054-P, 1062-P, 1082-P, 1084-P, 1085-P, 1086-P, 1088-P, 1093-P, 2549-PO
 Control 957-P
 Cooling detection threshold 642-P
 Corneal confocal microscopy 647-P, 651-P
 Corneal nerves 193-OR
 Coronary artery bypass graft surgery 1013-P
 Coronary artery calcification 444-P, 458-P, 491-P, 506-P, 1496-P, 2249-P
 Coronary artery disease 61-OR, 484-P, 493-P, 515-P, 638-P, 1246-P, 1567-P, 2703-PO
 Coronary computed tomography angiography 481-P
 Coronary heart disease; 1517-P
 Coronary smooth muscle cells 2828-PO
 Correlates of poor glycemic control 2652-PO
 Cortisol level 2491-PO
 Cost effectiveness 260-OR, 265-OR, 302-OR, 1339-P, 1346-P
 Cost implications 1348-P
 Cost of admission 1659-P
 Cost related medication non-adherence 305-OR
 Costs and length of stay 2633-PO
 Costs of diabetes 1328-P
 Counter regulatory response 1-OR, 394-P
 County prevalence 1674-P
 C-peptide 622-P, 1050-P, 1801-P, 2916-PO
 CPR 1112-P
 C-reactive protein 469-P, 1616-P
 Creatinine 2741-PO
 Critical limb ischemia 139-OR
 Cultural barriers 1326-P
 Cumulative incidence diabetes 1532-P
 Curcumin supplementation 1291-P
 Curcumin 574-P, 2003-P
 Cyclosporine 113-OR
 Cystatin C 141-OR
 Cystic fibrosis 1387-P
 Cytokeratin-18 fragments 688-P
 Cytokine 497-P, 616-P, 794-P, 1825-P
 Cytoskeleton 1898-P, 1920-P
 DACRA 1098-P
 Daily acute glucose fluctuation 1230-P
 Daily energy intake 2490-PO
 Daily vitamin intake 2490-PO
 Danhong injection 1616-PO
 Dapagliflozin 15-OR, 103-OR, 104-OR, 105-OR, 106-OR, 108-OR, 1174-P, 1175-P, 1176-P, 1179-P, 1198-P, 1204-P, 1208-P, 1210-P, 1211-P, 1212-P, 1216-P, 1217-P, 1223-P, 1224-P, 1225-P, 1228-P, 1239-P, 1243-P, 1249-P, 1253-P, 1254-P, 1255-P, 1256-P, 1275-P, 1278-P, 1279-P, 1357-P, 2582-PO, 2584-PO, 2585-PO, 2598-PO, 2604-PO
 Data integration 1787-P
 Data repository 960-P
 Daytime sleepiness 501-P
 Dedifferentiation 2259-P, 2299-P, 2310-P
 Degludec 1051-P, 2534-PO
 Delivery of insulin to the brain 1917-P
 Delivery timing 1464-P
 Dementia 628-P, 1483-P
 Demography 1693-P
 Dental loss 1600-P
 Dental pulp stem cell 617-P
 Depression 214-OR, 843-P, 846-P, 847-P, 867-P, 869-P, 871-P, 876-P, 877-P, 906-P, 922-P, 931-P, 1661-P, 1706-P, 1781-P, 2431-PO, 2506-PO, 2738-PO
 Depression collaborative care 302-OR
 Desaturase 1713-P
 Designer g-protein coupled receptors 372-OR
 Developing countries 784-P, 789-P
 Developing diabetes 1199-P
 Developmental delay in offspring 1437-P
 Developmental origins of health and disease 1444-P
 DFU 2458-PO
 Diabetes 50-OR, 142-OR, 190-OR, 254-OR, 301-OR, 663-P, 691-P, 695-P, 700-P, 715-P, 768-P, 786-P, 817-P, 848-P, 857-P, 893-P, 1205-P, 1358-P, 1393-P, 1409-P, 1557-P, 1589-P, 1590-P, 1660-P, 1680-P, 1697-P, 1709-P, 1786-P, 1918-P, 2003-P, 2085-P, 2251-P, 2408-PO, 2438-PO, 2598-PO, 2626-PO, 2638-PO, 2647-PO, 2719-PO, 2827-PO, 2830-PO, 2883-PO
 Diabetes and body mass index 1845-P
 Diabetes and cancer 1693-P, 2503-PO
 Diabetes and chronic kidney disease 1325-P, 1336-P
 Diabetes and coronary artery disease 1488-P
 Diabetes and prediabetes incidence 1704-P
 Diabetes associated HCC 2859-PO
 Diabetes camp 2498-PO
 Diabetes care improvement model 1348-P
 Diabetes certificate 780-P
 Diabetes complications 390-P, 908-P, 933-P, 1580-P, 1642-P, 2737-PO
 Diabetes control 876-P, 2908-PO
 Diabetes definition 1527-P
 Diabetes diagnosis 2707-PO
 Diabetes distress and depression 880-P
 Diabetes distress 846-P, 847-P, 2507-PO
 Diabetes education 210-OR, 745-P, 747-P, 753-P, 764-P, 765-P, 773-P, 776-P
 Diabetes glucose accuracy self-monitoring 944-P
 Diabetes in pregnancy 1442-P, 1465-P, 2658-PO
 Diabetes incidence 696-P, 1528-P, 1540-P, 2703-PO
 Diabetes information sources 2464-PO
 Diabetes management 882-P, 907-P, 1371-P
 Diabetes prediction 151-OR
 Diabetes prevalence 1662-P, 1696-P
 Diabetes prevention 213-OR, 299-OR, 751-P, 752-P, 856-P, 874-P, 1195-P, 1368-P, 1639-P, 2497-PO
 Diabetes related complications 1614-P
 Diabetes related distress 215-OR, 887-P
 Diabetes related quality of life 1418-P
 Diabetes remission 2176-P, 2239-P
 Diabetes risk 1645-P
 Diabetes screening 2718-PO, 2727-PO
 Diabetes self-efficacy 918-P
 Diabetes self-management 784-P, 789-P, 888-P, 917-P, 921-P
 Diabetes skin aging 624-P
 Diabetes symptoms 865-P
 Diabetes technology 2504-PO
 Diabetes transition services 2632-PO
 Diabetes treatment 849-P, 1812-P
 Diabetes with comorbid hypertension 2696-PO
 Diabetic autonomic neuropathy 1515-P
 Diabetic awareness 2717-PO
 Diabetic cardiomyopathy 59-OR 470-P, 474-P, 1298-P
 Diabetic dyslipidemia 252-OR, 689-P, 703-P, 704-P, 712-P
 Diabetic education 782-P
 Diabetic family history 2720-PO
 Diabetic foot 139-OR, 140-OR, 718-P, 720-P, 726-P, 735-P, 1611-P, 2459-PO
 Diabetic foot ulcer 141-OR, 719-P, 722-P, 728-P, 732-P, 734-P, 738-P, 1378-P, 2812-PO
 Diabetic gastroparesis 1304-P, 2736-PO
 Diabetic ketoacidosis 268-OR, 356-OR, 709-P, 2632-PO, 2644-PO, 2650-PO, 2657-PO, 2676-PO
 Diabetic kidney disease 592-P, 600-P, 1305-P, 1591-P, 1890-P
 Diabetic macular edema 287-OR, 289-OR, 290-OR, 682-P
 Diabetic monkey 1103-P
 Diabetic nephropathy 79-OR, 82-OR, 83-OR, 536-P, 541-P, 543-P, 544-P, 547-P, 549-P, 550-P, 560-P, 563-P, 569-P, 571-P, 573-P, 581-P, 582-P, 585-P, 594-P, 596-P, 608-P, 609-P, 613-P, 1539-P, 1591-P, 1608-P, 1609-P, 2415-PO, 2416-PO, 2417-PO, 2422-PO, 2424-PO, 2425-PO, 2426-PO, 2654-PO
 Diabetic neuropathic pain 2432-PO
 Diabetic neuropathy 189-OR, 191-OR, 192-OR, 193-OR, 623-P, 632-P, 634-P, 644-P, 658-P

- 659-P, 1548-P, 2405-PO, 2430-PO, 2431-PO, 2433-PO
 Diabetic neuropathy sural nerve conduction 2429-PO
 Diabetic neuropathy symptoms score 659-P
 Diabetic phenotype 1973-P
 Diabetic polyneuropathy 195-OR
 Diabetic retinopathy 283-OR, 286-OR, 402-P, 660-P, 667-P, 668-P, 669-P, 672-P, 673-P, 675-P, 676-P, 677-P, 684-P, 1299-P, 1407-P, 1797-P, 2448-PO
 Diabetic wound 721-P
 Diacylglycerol 816-P
 Diagnosis post-prandial glucose 2723-PO
 Diagnosis 636-P, 1457-P, 1458-P, 1661-P
 Diagnostic criteria 1567-P
 Dialogue tools 753-P
 Diastolic dysfunction 807-P, 2393-PO
 Diet 88-OR, 766-P, 1630-P, 2010-P, 2471-PO
 Dietary acid load 1623-P
 Dietary fat and protein 85-OR
 Dietary fat clearance 2190-P
 Dietary fiber 826-P, 2485-PO
 Dietary patterns 1727-P
 Dietary protein 1632-P
 Dietary supplements 2749-PO
 Diet-induced obesity 2168-P
 Diet-induced weight loss 2216-P
 Dietitian 92-OR
 Diffusion tensor imaging 1603-P
 Digital glucose monitoring 1453-P
 Dilated eye exam 761-P, 1607-P
 DIO rats food preference 1140-P
 Dipeptidyl peptidase-4 113-OR, 123-OR, 434-P, 489-P, 555-P, 578-P, 1214-P, 1218-P, 1230-P, 1245-P, 1247-P, 1703-P, 1829-P, 1852-P, 1916-P, 2142-P, 2344-P, 2442-PO, 2623-PO
 Direct medical costs 2642-PO
 Disability 751-P
 Disability-free life years 1472-P
 Discharge 1332-P
 Discontinuation 1047-P, 1476-P
 Discover 2746-PO
 Disparities 886-P, 1582-P, 1666-P
 Diurnal glucose variability 1147-P, 1396-P
 DLK1 1972-P
 DM treatment 2781-PO
 DM-2 hospitalizations 1659-P
 DNA methylation 1794-P, 1954-P
 Doc2b 1899-P
 Doctor-patient communication 1324-P
 Dogs 2378-PO
 Dopamine 1998-P, 2042-P, 2044-P, 2109-P
 Down-titration 1047-P
 DPP-4 inhibitor 104-OR, 540-P, 558-P, 559-P, 563-P, 708-P, 1179-P, 1188-P, 1208-P, 1232-P, 1248-P, 1250-P, 1252-P, 1254-P, 1256-P, 1258-P, 1264-P, 1269-P, 1270-P, 2075-P, 2145-P, 2407-PO, 2580-PO, 2600-PO
 Drama 2508-PO
 Driving 425-P, 783-P, 863-P
 Drug induced liver injury 989-P
 Drug targeting 2383-PO
 Drug therapy 2761-PO
 Dry eye disease 685-P
 DsbA-L 337-OR
 Dulaglutide 280-OR, 1014-P, 1110-P, 1114-P, 1127-P, 1134-P, 1135-P
 Duodenal-jejunal bypass liner 242-OR, 2180-P
 Durability 150-OR, 2177-P
 Duration 69-OR
 DVT 726-P
 Dynamics 391-P
 Dysglycemia 258-OR
 Dysglycemia in pregnancy 1657-P
 Dyslipidemia 257-OR, 258-OR, 428-P, 602-P, 693-P, 695-P, 696-P, 700-P, 701-P, 706-P, 711-P, 715-P, 2449-PO, 2451-PO
 Early detection 1718-P
 Early growth genetics 23-OR
 Early response 1365-P
 ECHO 779-P
 Economic burden 1328-P
 Economic costs 873-P
 Ectonucleotidases 1837-P
 Ectopic fat 1385-P, 1663-P, 2201-P
 Education 744-P, 780-P, 783-P, 891-P, 1086-P, 2466-PO, 2467-PO
 Effect of migration 2507-PO
 Effectiveness of oral glucose lowering therapy 2581-PO
 eGFR 107-OR, 591-P
 EHR diabetes clinical decision support 1377-P
 Ejection fraction non-human primates 1508-P
 Elderly 264-OR, 782-P, 991-P, 1014-P, 1360-P, 1612-P, 2298-P, 2684-PO, 2685-PO
 Elective surgery 1352-P
 Electrochemical Skin Conductance 614-P
 Electron microscopy 137-OR
 Electronic health record 1330-P, 1705-P
 Electronic medical recording system 923-P
 Elevated nocturnal blood pressure 621-P
 Embryo metabolism 368-OR
 Embryonic stem cells 729-P
 Embryopathy 368-OR
 Emergency medicine 754-P, 1665-P, 1677-P, 2374-PO
 Emerging adulthood 919-P
 Emotional distress 1560-P
 Empagliflozin 435-P, 1173-P, 1213-P, 1241-P, 1259-P, 1276-P, 2594-PO
 Endobarrier 967-P, 2217-P, 2240-P
 Endocannabinoid system 2000-P, 2224-P
 Endocrine progenitors cytokines 2310-P
 Endocrinologist access 1319-P
 Endogenous glucose production 46-OR, 1959-P, 1968-P
 Endoplasmic reticulum 134-OR, 681-P, 1894-P, 2274-P, 2871-PO
 Endoscopy 2736-PO
 Endothelial aging 2410-PO
 Endothelial cell 670-P, 1910-P
 Endothelial dysfunction 482-P, 519-P, 534-P, 911-P, 1293-P, 2408-PO
 Endothelial function 467-P, 490-P, 599-P, 826-P, 2433-PO
 Endothelial progenitor cells 581-P, 2392-PO, 2901-PO
 Endothelium 2412-PO
 Energy balance 1988-P, 1997-P
 Energy expenditure 2114-P
 Energy intake 2006-P
 Enhancer 561-P, 1753-P
 eNOS 2108-P, 2836-PO
 ENPP-1 2237-P
 Enteroendocrine cells 2054-P
 Environmental exposures 1574-P
 Environmental metal exposure 1647-P
 Eosinophil 2154-P
 EPA 705-P
 Epac 2034-P
 Epicardial adipose tissue 426-P, 450-P
 ePID closed loop system 220-OR
 Epidemology 156-OR, 389-P, 1394-P, 1513-P
 Epidermal growth factor receptor 711-P
 Epigenetic biomarker 1760-P
 Epigenetics DNA methylation 308-OR
 Epigenetics 1424-P, 1815-P, 2152-P
 Epigenomics 561-P, 1753-P
 Epinephrine 2702-PO
 Epithelial-mesenchymal transition 576-P
 ePRO 879-P
 Epsins 2131-P
 eQTL 311-OR
 ER stress 130-OR, 131-OR, 243-OR, 2101-P, 2255-P, 2260-P, 2262-P, 2266-P, 2269-P, 2277-P, 2287-P, 2319-P
 Erectile dysfunction 1303-P, 1598-P
 ERK1/2 2111-P
 ERRA 2136-P
 Ertugliflozin 2605-PO
 Erythropoietin 1919-P, 2106-P, 2816-PO
 ESRD 591-P
 Essential oil 740-P
 Estrogen receptors 1775-P
 Estrogen 131-OR, 2936-PO
 Ethnic components 1783-P
 Ethnic groups 1736-P
 Ethnicity 71-OR, 1446-P, 2711-PO
 Euglycemic hyperinsulinemic clamp 2878-PO
 Examination 12-OR, 717-P
 Excessive daytime sleepiness 860-P
 Excessive gestational weight gain 1463-P
 Excitotoxicity 2110-P
 Executive function 882-P
 Exenatide once weekly 1162-P
 Exenatide twice daily 2552-PO
 Exenatide 276-OR, 1107-P, 1108-P, 1115-P, 1120-P, 1129-P, 1161-P, 1649-P, 2554-PO, 2568-PO, 2574-PO
 Exercise 175-OR, 291-OR, 292-OR, 294-OR, 296-OR, 375-OR, 791-P, 804-P, 810-P, 812-P, 814-P, 818-P, 823-P, 996-P, 1059-P, 2470-PO, 2476-PO, 2511-PO
 Exercise capacity 1387-P
 Exercise heart rate ratio method 2474-PO
 Exercise in pregnancy 820-P
 Exercise intensity 819-P
 Exercise lean body mass 817-P
 Exercise metabolic flux analysis 800-P
 Exercise muscle perfusion 298-OR
 Exercise signaling 297-OR
 Exercise training 2473-PO
 Exocytosis 2314-P, 2346-P
 Exosomes 530-P, 1549-P
 Expenditures 1351-P
 Extended wear 955-P
 Extracellular matrix 738-P, 2150-P
 FABP5 2117-P
 Fall risk 643-P
 Familial conflict 913-P
 Familial diabetes 438-P, 1776-P
 Family 204-OR, 2466-PO
 Family awareness 785-P
 Family communication 894-P
 Family history of diabetes 1534-P
 Family planning vigilance 212-OR
 Family studies 312-OR
 Family support 759-P, 775-P, 853-P
 Family-based interventions 921-P
 Fasiglifam 2338-P
 Faster-acting insulin aspart 1024-P
 Fasting dyslipidemia 251-OR

- Fasting glycemia 2015-P
 Fasting index 1551-P
 Fasting plasma glucose 1275-P
 Fasting status 1526-P
 Fat browning 1864-P
 Fat distribution 332-OR
 Fat mass accrual 1434-P
 Fat mass 2854-PO
 Fat quality 841-P
 Fatty acid availability 2212-P
 Fatty acid composition 708-P
 Fatty acid metabolism 716-P
 Fatty acid oxidation 1982-P
 Fatty acid proportion 1713-P
 Fatty acid synthesis and oxidation 41-OR
 Fatty acids 87-OR, 830-P, 2354-P
 Fatty liver 126-OR, 830-P, 1688-P, 1956-P, 1976-P, 2795-PO
 FDG PET 2051-P
 Febrile 2852-PO
 Feeding entrainment 2059-P
 Femoral posterior tibial pulse wave velocity 509-P
 Fenofibrate 679-P
 Ferritin 1967-P
 Fetal biometry 1442-P
 Fetal programming 381-OR, 1424-P, 1427-P, 1438-P, 1448-P
 FFAR1/GPR40 agonist 2338-P
 FGF-19 242-OR
 FGF21 1866-P, 1908-P, 1962-P, 2060-P, 2071-P, 2823-PO, 2913-PO
 FIAsp 976-P, 983-P, 994-P, 1005-P
 Fibroblast growth factor 21 479-P, 495-P, 2048-P, 2238-P, 2857-PO
 Fibrosis 548-P, 552-P
 Fibrovascular membrane 677-P
 Finnish diabetes risk score 2206-P
 First-line medication 1272-P
 Fitness 84-OR, 2912-PO
 Fitness change 154-OR
 Fixed-dose combination 1218-P, 1247-P
 Fixed-ratio combination 169-OR
 Flow cytometry 2244-P
 Flow occlusion 1071-P
 Focal adhesion kinase 1858-P
 Folate 1470-P
 Follow-up after discharge 1361-P
 Follow-up 2572-PO
 Food choice 125-OR
 Food insecurity 382-OR, 1619-P, 1653-P, 2389-PO
 Food intake 1991-P, 2000-P, 2871-PO, 2915-PO
 Food pantries 824-P
 Foot 741-P
 Foot ulcer 733-P, 739-P
 Forearm extraction 2870-PO
 Formula diet 837-P
 FOXO1 328-OR, 2080-P
 FOXP3 1806-P
 Frailty syndrome 2637-PO
 Free fatty acid receptor-2 363-OR
 Free fatty acids 78-OR, 2098-P, 2235-P, 2801-PO, 2821-PO
 Free radicals 1817-P
 Frequent interventions 1380-P
 Fructosamine 1542-P
 Fructose metabolism 124-OR
 Fructose 575-P, 1956-P
 Functional connectivity 8-OR
 Functional magnetic resonance imaging 45-OR
 Functional studies 314-OR
 Fundus camera 682-P
 Fyn 118-OR, 2104-P
 Gallic acid 839-P
 Gamma-glutamyltransferase 1547-P
 Gastric bypass 240-OR, 2076-P, 2194-P, 2208-P, 2233-P
 Gastric electrical stimulation 1307-P
 Gastric inhibitory polypeptide 2061-P, 2086-P, 2117-P, 2811-PO
 Gastrin 2085-P
 Gastrointestinal enteroendocrine 2288-P
 Gastrointestinal hormones 825-P
 Gastrointestinal symptoms 1316-P
 Gastrointestinal tract 1921-P
 GCK 1949-P
 Gender 771-P, 785-P, 1007-P
 Gene expression profiles 1824-P, 1883-P, 1943-P, 2789-PO
 Gene regulation 2304-P
 Gene-gene interaction 1796-P
 Genetic association 57-OR, 1799-P, 2191-P
 Genetic interaction map 245-OR
 Genetic prediction 1788-P
 Genetic risk 73-OR, 152-OR, 1789-P, 1793-P
 Genetic variants 313-OR
 Genetics 310-OR, 459-P, 480-P, 493-P, 1598-P, 1741-P, 1742-P, 1743-P, 1744-P, 1747-P, 1754-P, 1755-P, 1764-P, 1778-P, 2221-P
 Genital mycotic infections 1178-P
 Genome wide association study 19-OR, 20-OR, 21-OR, 22-OR, 24-OR, 314-OR, 1592-P, 1757-P, 1770-P, 1779-P, 2730-PO
 Genotype 2789-PO
 Geochemical data 1737-P
 Geographic information system 1319-P
 Geriatric diabetes 407-P
 Gestational diabetes 144-OR, 148-OR, 149-OR, 362-OR, 369-OR, 690-P, 788-P, 1368-P, 1425-P, 1428-P, 1430-P, 1431-P, 1433-P, 1435-P, 1436-P, 1437-P, 1439-P, 1440-P, 1441-P, 1443-P, 1445-P, 1447-P, 1450-P, 1452-P, 1453-P, 1454-P, 1457-P, 1458-P, 1460-P, 1466-P, 1467-P, 1469-P, 1470-P, 1541-P, 1568-P, 2497-PO, 2502-PO, 2662-PO, 2664-PO, 2666-PO, 2667-PO, 2669-PO, 2670-PO, 2671-PO, 2673-PO, 2675-PO, 2676-PO, 2678-PO, 2679-PO, 2680-PO, 2682-PO
 Gestational outcomes 1449-P
 Gestational weight gain 155-OR, 1434-P
 Ghrelin 2074-P
 GIP GLP-1 2350-P
 Glargine insulin 1011-P
 Glargine metabolism 1012-P
 Glargine 93-OR, 95-OR, 280-OR, 984-P, 985-P, 986-P
 Global diabetes surveillance 1527-P
 Global positioning systems 736-P
 Glomerular filtration rate 110-OR
 Glomerular pathophysiology 553-P
 GLP-1 25-OR, 122-OR, 128-OR, 159-OR, 164-OR, 165-OR, 168-OR, 173-OR, 279-OR, 281-OR, 1105-P, 1106-P, 1121-P, 1130-P, 1142-P, 1144-P, 1148-P, 1149-P, 1152-P, 1153-P, 1171-P, 1182-P, 1300-P, 2050-P, 2062-P, 2064-P, 2069-P, 2077-P, 2078-P, 2082-P, 2089-P, 2090-P, 2119-P, 2122-P, 2149-P, 2200-P, 2213-P, 2219-P, 2229-P, 2314-P, 2553-PO, 2558-PO, 2561-PO, 2565-PO, 2569-PO, 2570-PO, 2576-PO, 2577-PO, 2879-PO
 GLP-1 receptor agonists 278-OR, 282-OR, 285-OR, 600-P, 1104-P, 1112-P, 1122-P, 1140-P, 1151-P, 1158-P, 1215-P, 1994-P, 2051-P, 2130-P, 2233-P, 2566-PO
 Glucagon 1952-P
 Glucagon counterregulation 1104-P
 Glucagon delivery 1077-P
 Glucagon 236-OR, 316-OR, 328-OR, 398-P, 1141-P, 1202-P, 1933-P, 1948-P, 1955-P, 2041-P, 2081-P, 2083-P, 2099-P, 2119-P, 2619-PO
 Glucagon-like peptide 123-OR, 256-OR, 532-P, 698-P, 1109-P, 1125-P, 1155-P, 1160-P, 1193-P, 1497-P, 1922-P, 2056-P, 2163-P
 Glucocorticoids 1240-P, 1930-P, 2155-P, 2205-P, 2360-P
 Glucokinase 1165-P, 1167-P, 1168-P, 1271-P, 1294-P, 1435-P, 2318-P, 2667-PO
 Glucolipototoxicity 2069-P, 2331-P, 2348-P
 Glucometer 963-P
 Glucometrics 2633-PO
 Gluconeogenesis 127-OR, 1945-P, 1965-P, 1975-P
 Glucosamine 626-P
 Glucose 1456-P, 1759-P, 1906-P, 2710-PO
 Glucose and lipid metabolism 1902-P
 Glucose clamp 978-P, 979-P, 1019-P
 Glucose control 2749-PO
 Glucose counterregulation 2-OR
 Glucose homeostasis 1942-P, 2007-P
 Glucose intolerance 2228-P
 Glucose metabolism 792-P, 1183-P, 1426-P, 1626-P, 1766-P, 1876-P, 2016-P, 2659-PO, 2915-PO
 Glucose monitoring 957-P, 973-P
 Glucose oxidase 963-P
 Glucose prediction 962-P
 Glucose profile 954-P
 Glucose sensing 935-P, 2931-PO
 Glucose stimulated insulin secretion 1935-P, 1943-P
 Glucose strip 951-P
 Glucose tolerance 1428-P, 2175-P
 Glucose toxicity 326-OR
 Glucose uptake 1889-P, 1898-P, 1900-P
 Glucose variability 181-OR, 653-P, 2444-PO
 Glucose-dependent insulinotropic polypeptide 477-P, 2097-P
 Glucose-sensing receptor 53-OR
 Glucose-stimulated insulin secretion 341-OR
 Glucostatic parameters 2014-P
 Glucosuria 1791-P
 Glucotoxicity 2335-P, 2412-PO
 GLUT-4 1895-P, 1896-P, 1899-P, 2489-PO
 Glutathione 2924-PO
 Glycaemic control 1170-P, 1188-P
 Glycaemic streaming 2672-PO
 Glycaemic variability 1042-P
 Glycated albumin 598-P, 823-P, 958-P, 969-P, 1542-P, 1562-P, 1576-P, 2402-PO, 2710-PO
 Glycated hemoglobin 73-OR, 1584-P, 1754-P, 2095-P
 Glycation 534-P
 Glycemic control 772-P, 820-P, 867-P, 1055-P, 1136-P, 1149-P, 1157-P, 1162-P, 1169-P, 1192-P, 1323-P, 1403-P, 1601-P, 1652-P, 1676-P, 1687-P, 1729-P, 1730-P, 2538-PO, 2593-PO, 2625-PO, 2708-PO, 2786-PO
 Glycemic management system 604-P, 1067-P, 1092-P
 Glycemic status 931-P, 2804-PO
 Glycemic trait genetics 1756-P
 Glycemic variability 167-OR, 971-P, 1286-P, 1715-P, 2513-PO
 Glycerol metabolism 1856-P
 Glycogen synthesis 124-OR, 2016-P
 Glycogen 4-OR, 2383-PO
 Glycoprotein 130 1881-P

- Gout 1720-P
 GPR120 1242-P, 1284-P, 2011-P, 2336-P
 GPR40 2082-P, 2365-P
 GPX 533-P
 Graft survival 109-OR
 Group medical visits 1363-P
 Growth factor 2306-P
 Growth 1921-P
 GSK3 2411-PO
 GSK3-beta 2370-P
 Guidelines 1667-P
 Gurmar 2622-PO
 Gut microbiota 30-OR, 89-OR, 363-OR, 1263-P
 Gut peptides 2913-PO
 Gut-derived glucagon 2063-P
 H. pylori infection 2100-P
 H9c2 cell line 2453-PO
 Half-life extension 2133-P
 Hallux Ulcer 731-P
 Haptoglobin genotype 464-P, 507-P, 1726-P
 HbA1c 215-OR, 773-P, 851-P, 1045-P, 1137-P,
 1284-P, 1332-P, 1393-P, 1422-P, 1530-P, 1574-P,
 1577-P, 1738-P, 1996-P, 2422-PO, 2724-PO,
 2728-PO
 HDL mimetic peptides 255-OR
 HDL 505-P, 528-P, 601-P, 687-P, 1189-P, 1777-P,
 2055-P
 Health and retirement study 1475-P
 Health care delivery 2662-PO
 Health care improvement 1325-P
 Health care research trial 747-P
 Health care resource utilization 1374-P
 Health care transition 919-P
 Health delivery system 1323-P
 Health disparities due to poverty 1362-P
 Health economics 263-OR, 2545-PO, 2645-PO
 Health education 770-P
 Health equity 1402-P
 Health information technology 1660-P
 Health insurance 1335-P
 Health locus of control 918-P
 Health outcomes 997-P, 999-P, 1015-P, 1038-P
 Health professional education 2508-PO
 Health related quality of life 1351-P, 1583-P,
 2912-PO
 Health services research 303-OR
 Healthcare cost 259-OR, 1343-P, 1347-P
 Healthy days among patients with diabetes
 1583-P
 Healthy lifestyle intervention 869-P
 Healthy obese 2212-P
 Healthy prenatal behaviors 1657-P
 Heart 2124-P
 Heart disease in women 807-P
 Heart failure 450-P, 475-P, 1211-P, 1490-P, 1519-P
 Heart rate variability 282-OR, 447-P, 653-P, 1515-P,
 2434-PO, 2521-PO, 2566-PO
 Heart transplantation 1845-P
 Heart valve calcification 1581-P
 Heat shock factor 1 2255-P
 Heat shock protein 90 2020-P
 Hematopoietic cell transplantation 1094-P
 Hematopoietic stem cells 707-P
 Hemodialysis 171-OR, 832-P, 958-P, 2708-PO
 Hemodynamics 2077-P
 Hemoglobin A1c 149-OR, 483-P, 1474-P, 1525-P,
 1694-P 2527-PO, 2734-PO
 Hemoglobin glycation 1552-P
 Hemorheological 2426-PO
 Hepatic fatty acid partitioning 41-OR
 Hepatic fibrosis 1984-P
 Hepatic glucose production 2058-P, 2865-PO
 Hepatic glucose uptake 1946-P
 Hepatic glycogen 1946-P
 Hepatic insulin clearance 1928-P
 Hepatic insulin resistance 1911-P, 1970-P, 2195-P
 Hepatic insulin sensitivity 1953-P
 Hepatic lipid accumulation 2173-P
 Hepatic lipid homeostasis 2101-P
 Hepatic lipid kinetics 2185-P
 Hepatic steatosis 251-OR, 1913-P, 1972-P
 Hepatic vein catheterisation 239-OR
 Hepatitis B 1358-P
 Hepatokine 2187-P, 2864-PO
 Hexokinase 1426-P, 2659-PO
 HFD-induced inflammation 1823-P
 HGF 2290-P
 HIF 556-P
 High density lipoproteins 198-OR
 High fat diet 485-P, 1993-P, 2015-P, 2127-P, 2149-P,
 2159-P
 High risk diabetes patients 2543-PO
 High starch diet 1995-P
 High-resolution peripheral quantitative computed
 tomography 686-P
 Hip fracture 1480-P
 Hippocampal volume 415-P
 Hippocampus 4-OR, 7-OR, 631-P, 2161-P
 hiPSCs 2372-P
 Hispanic 1510-P, 1719-P, 1780-P, 2753-PO
 Histology 2280-P
 Histone 324-OR, 1759-P
 HIV 1469-P
 HLA amino acids 307-OR, 1752-P, 1836-P
 HMG-CoA reductase 459-P, 1965-P, 2452-PO
 HNF-1 α 2325-P, 2934-PO
 HOMA IR 451-P
 Hormone 2067-P, 2879-PO
 Hospital 1268-P, 1356-P, 1364-P
 Hospital admission 1331-P
 Hospital diabetes team 1361-P
 Hospital glucose control 266-OR
 Hospitalization 268-OR, 400-P, 414-P, 418-P,
 1369-P, 1498-P, 1691-P, 2637-PO
 HPA axis 1991-P
 Human amylin 1804-P
 Human brown progenitors 2179-P
 Human islet transport 2281-P
 Human islets 137-OR, 345-OR, 2923-PO
 Human placenta 690-P
 Human regular U-500 insulin 988-P
 Human skeletal muscle 795-P
 Hyaluronidase 1139-P, 2557-PO
 Hybrid insulin peptides 32-OR
 Hyperbaric oxygen 655-P
 Hyperfiltration 608-P
 Hyperglucagonemia 129-OR
 Hyperglycemia 227-OR, 379-OR, 528-P, 1205-P,
 1792-P, 1880-P, 2478-PO, 2532-PO, 2877-PO,
 2933-PO
 Hyperinsulinemia 65-OR, 202-OR, 837-P, 1301-P,
 1951-P, 2099-P, 2318-P
 Hyperkalemia 1305-P, 2385-PO
 Hyperlipidemia 2454-PO
 Hypersensitivity 1204-P
 Hypertension 1176-P, 1417-P, 1572-P, 1589-P,
 2715-PO
 Hypertriglyceridemia 709-P, 1187-P, 2249-P,
 2251-P, 2419-PO
 Hyperuricemia 2763-PO
 Hypoglycemia 1-OR, 3-OR, 4-OR, 5-OR, 6-OR,
 7-OR, 98-OR, 241-OR, 347-OR, 348-OR, 350-OR,
 351-OR, 352-OR, 353-OR, 354-OR, 379-OR,
 386-P, 388-P, 389-P, 390-P, 391-P, 392-P, 393-P,
 394-P, 395-P, 396-P, 398-P, 399-P, 400-P, 402-P,
 404-P, 405-P, 407-P, 408-P, 409-P, 410-P, 412-P,
 413-P, 414-P, 416-P, 418-P, 419-P, 420-P, 422-P,
 423-P, 424-P, 943-P, 953-P, 966-P, 982-P, 987-P,
 993-P, 998-P, 1017-P, 1053-P, 1080-P, 1084-P,
 1095-P, 1290-P, 1322-P, 1339-P, 1350-P, 1485-P,
 1586-P, 1968-P, 2345-P, 2374-PO, 2375-PO,
 2376-PO, 2377-PO, 2378-PO, 2380-PO,
 2384-PO, 2385-PO, 2387-PO, 2389-PO,
 2390-PO, 2521-PO, 2552-PO, 2642-PO, 2896-PO
 Hypothalamic gliosis 158-OR
 Hypothalamus 122-OR, 2103-P, 2116-P
 Hypoxia 441-P, 2245-P, 2282-P
 Iberivillea sonorae 2607-PO
 Ileal transposition 2088-P
 IMCL 44-OR
 Imeglimin 1169-P
 Immune function 1252-P
 Immune tolerance 187-OR
 Immune-metabolic response 1805-P
 Immunoglobulin M 1821-P
 Immunoisolation 1842-P
 Immunometabolism 2154-P
 Immunomodulation 233-OR
 Immunoregulation 1812-P
 Impact 2775-PO
 Impaired fasting glucose 1494-P, 1551-P, 1688-P,
 2195-P
 Impaired glucose regulation 1716-P, 2454-PO
 Impaired glucose tolerance 72-OR, 1154-P, 1484-P,
 1537-P, 1554-P, 2313-P
 Implantable glucose monitoring device 972-P
 Imprinting 2271-P
 IMT 439-P, 452-P
 In vitro pharmacology 1033-P
 In vivo adipogenesis 331-OR
 Incidence 77-OR, 1556-P, 1735-P, 1737-P
 Incident diabetes 1523-P, 1624-P
 Incidentally diagnosed diabetes 1691-P
 Incretin dulaglutide 1132-P
 Incretin effect 1440-P
 Incretin hormone biosynthesis 2063-P
 Incretin hormones 1936-P, 2073-P
 Incretin 586-P, 1157-P, 2047-P, 2061-P, 2066-P,
 2086-P, 2093-P, 2097-P, 2882-PO
 Incretin-based diabetes medication 10-OR
 India 2709-PO
 Indigenous children 927-P, 1389-P
 Induced pluripotent stem cells 728-P
 Infant adiposity 147-OR
 Infection 1250-P, 1590-P
 Infection and diabetes 1588-P
 Infection disease 1675-P
 Infectious complications 2800-PO
 Inflammasome 1762-P
 Inflammation 507-P, 571-P, 592-P, 619-P, 671-P,
 821-P, 971-P, 1141-P, 1822-P, 1830-P, 1835-P,
 1851-P, 1934-P, 2008-P, 2027-P, 2045-P, 2049-P,
 2123-P, 2193-P, 2424-PO
 Inflammation and bone turnover 502-P
 Inflammation in exercise 796-P
 Inflammation in pediatric obesity 1388-P
 Inflammation resistance 2243-P
 Inflammatory markers 348-OR
 Influenza vaccination 1700-P
 Information and communication technology
 2494-PO
 Infusion set failures 1076-P
 Infusion set 2557-PO

- Inhaled insulin 978-P, 1028-P
 Inhibition of the insulin receptor in amygdala 2170-P
 Initial treatment 2510-PO
 Injectable insulin 1341-P, 1344-P
 Injectables 1126-P
 Injection site pain 1161-P
 Injection site treatment 1075-P
 iNKT cells 25-OR
 Innate immunity 31-OR
 iNOS 49-OR
 Inositol 531-P
 Inpatient 410-P, 776-P, 1356-P, 2377-PO
 Inpatient diabetes protocol 1013-P
 Inpatient diabetes 1090-P, 1345-P
 Inpatient glucose 76-OR, 1345-P
 Inpatient hypoglycemia 774-P
 Inpatient insulin therapy 1043-P
 Inpatient management 769-P, 1095-P
 Insulin 100-OR, 168-OR, 322-OR, 763-P, 1040-P, 1042-P, 1065-P, 1166-P, 1245-P, 1249-P, 1615-P, 1856-P, 2356-P, 2532-PO, 2537-PO, 2540-PO, 2629-PO, 2759-PO, 2780-PO, 2822-PO, 2832-PO
 Insulin absorption 1039-P, 1057-P, 1069-P
 insulin action 252-OR, 1988-P
 Insulin administration 1089-P
 Insulin analogue 2628-PO
 Insulin aspart 766-P
 Insulin catabolism 1262-P
 Insulin clamp 802-P
 Insulin clearance 1951-P
 Insulin costs 1375-P
 Insulin degludec 166-OR, 1002-P, 1003-P, 1009-P, 1035-P, 1150-P, 1408-P, 2533-PO, 2550-PO
 Insulin delivery 1077-P, 1083-P, 1087-P, 1091-P, 2546-PO
 Insulin dosage 961-P
 Insulin dose reduction 2379-PO
 Insulin dosing 85-OR
 Insulin glargine 98-OR, 987-P, 991-P, 1017-P, 1021-P, 1026-P, 1027-P, 1030-P, 1048-P, 1052-P, 1915-P, 2533-PO
 Insulin infusion sets 1071-P
 Insulin infusion 1376-P, 2702-PO
 Insulin initiation 1338-P, 1399-P
 Insulin injection skills 781-P
 Insulin intensification 2770-PO
 Insulin lipogenesis 1969-P
 Insulin lispro 1129-P
 Insulin needle 2544-PO
 Insulin pharmacodynamics 1075-P
 Insulin prescribing 2463-PO
 Insulin pump downloads 2512-PO
 Insulin pump infusion set 1064-P
 Insulin pump therapy 607-P, 777-P, 968-P, 1054-P, 1055-P, 1056-P, 1068-P, 1364-P, 2545-PO
 Insulin pumps 1073-P
 Insulin reactions 2682-PO
 Insulin receptor harmonic oscillator model 1032-P
 Insulin receptor signaling 2368-P
 Insulin receptor 197-OR, 248-OR, 318-OR, 319-OR, 1877-P, 1947-P, 1985-P, 2285-P
 Insulin regimen in youth with diabetes 2652-PO
 Insulin resistance effects on development 1963-P
 Insulin resistance indexes 510-P
 Insulin resistance 65-OR, 74-OR, 158-OR, 235-OR, 380-OR, 381-OR, 436-P, 626-P, 803-P, 821-P, 836-P, 1020-P, 1226-P, 1505-P, 1538-P, 1701-P, 1805-P, 1854-P, 1863-P, 1878-P, 1884-P, 1901-P, 1902-P, 1909-P, 1913-P, 1914-P, 1922-P, 1928-P, 1947-P, 1958-P, 1966-P, 1975-P, 1979-P, 2002-P, 2022-P, 2023-P, 2039-P, 2049-P, 2124-P, 2137-P, 2178-P, 2181-P, 2205-P, 2479-PO, 2573-PO, 2712-PO, 2745-PO, 2797-PO, 2805-PO, 2809-PO, 2821-PO, 2837-PO, 2839-PO
 Insulin response 2001-P
 Insulin safety 2463-PO
 Insulin secretion 48-OR, 238-OR, 339-OR, 346-OR, 1244-P, 1386-P, 1533-P, 1927-P, 1932-P, 1938-P, 1939-P, 1940-P, 1941-P, 2317-P, 2325-P, 2339-P, 2350-P, 2352-P, 2359-P, 2579-PO, 2932-PO
 Insulin secretory function 1576-P
 Insulin secretory machinery 2351-P
 Insulin sensitivity 120-OR, 298-OR, 835-P, 1081-P, 1563-P, 1618-P, 1796-P, 1872-P, 1905-P, 1940-P, 1961-P, 2009-P, 2094-P, 2183-P, 2471-PO
 Insulin sensitization 2823-PO
 Insulin sensitizer 1196-P, 1879-P
 Insulin signaling 119-OR, 316-OR, 318-OR, 1865-P, 2083-P, 2364-P, 2828-PO
 Insulin storage 1892-P
 Insulin therapy 172-OR, 885-P, 1160-P, 1489-P, 2744-PO
 Insulin titration 1011-P
 Insulin transport 1910-P, 1925-P
 Insulin use 1652-P
 Insulin-like growth factor-2 20-OR
 Insulin-like growth factor-1 2029-P
 Insulin-like growth factor-binding protein 1904-P
 Insulin-sensitive organs 2882-PO
 InsuPad 1057-P, 1069-P
 Insupatch 1078-P
 Insurance 1677-P
 Integrated network analysis 576-P
 Integrated sensor 949-P
 Integration of care 2635-PO
 Integrative genomics 1758-P
 Integrative medicine 2462-PO
 Integrin 540-P, 1904-P, 1971-P
 Intensive glucose control 114-OR
 Intensive insulin therapy 179-OR, 1031-P
 Intensive treatment 393-P
 Interesterified fat 2889-PO
 Interferon gamma 1749-P
 Interim data 929-P
 Interleukin-1 beta vaccine 1100-P
 Interleukin-1 beta 344-OR
 Interleukin-27 2167-P
 Interleukin-6 288-OR, 1853-P
 Intermediary metabolism 2853-PO
 Internal radiation 2031-P
 International comparison 1096-P, 1710-P, 1730-P
 Internet 768-P
 Internet program 852-P
 Internet resources 1405-P
 Internet use 770-P
 Interstitial glucose 941-P
 Intervention in high risk families 2502-PO
 Intestinal glucose absorption 2517-PO, 2587-PO
 Intestinal glucose uptake 2473-PO
 Intestinal lipid sensing 1959-P
 Intima-media thickness 458-P, 503-P, 512-P, 1733-P
 Intra hepatic lipid and liver function tests 1961-P
 Intrahepatic lipid 2450-PO
 Intrahepatic triglyceride 39-OR
 Intramuscular glucagon 1060-P
 Intramyocellular lipid 819-P
 Intranasal insulin administration 1917-P
 Intraoperative glucose 1008-P, 1366-P
 Intra-pancreatic fat 2202-P
 Intravitreal aflibercept injection 289-OR
 Ipragliflozin 1203-P
 iPSC cells 246-OR, 380-OR, 1875-P, 2293-P
 IRF4 2128-P
 Irisin 818-P, 2906-PO
 Iron 601-P, 1893-P, 2189-P
 Iron metabolism 1901-P
 Iron overload 2866-PO
 Irs2 52-OR, 1888-P
 Islet 133-OR, 184-OR, 247-OR, 1807-P, 1934-P, 2265-P, 2307-P
 Islet adaptation 2930-PO
 Islet amyloid 182-OR, 2256-P, 2261-P, 2263-P, 2366-P
 Islet andeliac autoantibodies 1420-P
 Islet autoantibodies 1531-P, 1722-P, 1833-P
 Islet autoimmunity 1723-P, 1731-P
 Islet autotransplantation 1846-P
 Islet beta cell function 2321-P
 Islet biology 2280-P
 Islet dysfunction 344-OR
 Islet encapsulation 1844-P
 Islet isolation 188-OR
 Islet metabolism 2317-P
 Islet microencapsulation 1839-P
 Islet mitochondrial metabolism 340-OR
 Islet of langerhans 2156-P
 Islet proliferation small molecule 2291-P
 Islet proliferation 243-OR
 Islet transplant 109-OR, 110-OR, 111-OR, 112-OR, 115-OR, 187-OR, 1838-P
 ISO 15197 945-P
 Isoproterenol 2400-PO
 ITCA 650 276-OR, 1107-P
 Japanese 1231-P
 Jet injection 1089-P
 K2P channel 2349-P
 Kcnq1 2271-P
 Keller arthroplasty 731-P
 Ketoacidosis 273-OR
 Ketone body 1236-P
 Ketone metabolism 1883-P
 Kidney disease 604-P, 614-P, 1510-P
 Kidney dysfunction 1668-P
 Kidney function 1683-P
 Kidney injury 557-P, 575-P
 Kidney transplant surgery 1092-P
 Kinome interactome 2018-P
 Knowledge 872-P
 Knowledge outcomes 748-P
 Korean diabetes screening score 1704-P
 Kynurenine pathway 2328-P
 Labile iron 1967-P
 LADA 310-OR, 500-P, 2732-PO
 Laminin 2157-P
 Language concordance 1326-P
 Late stage complications 593-P
 Latinos Hispanics 2639-PO
 Latinos 382-OR, 755-P, 890-P, 920-P, 1561-P
 Lay user accuracy 2526-PO
 L-cell 1207-P
 LDL oxidation 705-P
 LDL-C 1296-P
 Legacy effect 1595-P
 Length of hospital stay 1373-P
 Length of stay and costs 266-OR
 Length of stay 769-P, 1043-P, 1355-P, 1370-P
 Lens autofluorescence 678-P, 2445-PO
 Leptin 403-P, 1753A-P, 2041-P, 2057-P, 2059-P, 2090-P, 2091-P, 2189-P

- Leucine based amino-acid infusion 164-OR
 Leucine 806-P, 1237-P, 2849-PO
 Leukocyte activation 796-P, 2012-P
 Levels of care 743-P
 Life years lost associated with diabetes 259-OR
 Lifestyle 855-P, 1501-P, 2793-PO
 Lifestyle change 2192-P
 Lifestyle counseling 1342-P
 Lifestyle interventions 265-OR, 752-P, 892-P, 1639-P, 1699-P
 Lifestyle modification intervention 925-P
 Lifetime risk diabetes 1532-P
 Limited joint mobility 727-P
 Linagliptin labeling 1267-P
 Linagliptin 539-P, 554-P, 1185-P, 1246-P, 1302-P, 2513-PO
 Linear models 1569-P
 Linkage analysis 1772-P, 1780-P
 Linkage 1769-P
 Lipemia 713-P
 Lipid droplet proteins 293-OR
 Lipid droplet 44-OR
 Lipid metabolism 293-OR, 1974-P, 1983-P, 2005-P, 2036-P, 2040-P
 Lipid profile 694-P
 Lipidome 2209-P
 Lipids 990-P
 Lipoatrophy 2535-PO
 Lipocalin 2 1857-P
 Lipodystrophic diabetes phenotype 2881-PO
 Lipodystrophy 1689-P, 1870-P, 2057-P, 2754-PO
 Lipogenesis 1288-P
 Lipohypertrophy 1000-P, 1019-P, 1375-P, 2744-PO
 Lipolysis glucose uptake Insulin resistance 1903-P
 Lipolysis 317-OR, 2130-P
 Lipolytic activity 1869-P
 Lipopolysaccharide 317-OR, 701-P, 2088-P
 Lipotoxicity 531-P, 2274-P, 2332-P, 2335-P, 2367-P, 2407-PO
 Tiraglutide improves insulin and leptin signaling 2112-P
 Tiraglutide 166-OR, 171-OR, 220-OR, 277-OR, 1002-P, 1003-P, 1009-P, 1117-P, 1128-P, 1146-P, 1148-P, 1150-P, 1156-P, 1163-P, 1306-P, 1309-P, 2213-P, 2229-P, 2550-PO, 2572-PO, 2575-PO, 2578-PO, 2684-PO, 2890-PO
 Lispro 2537-PO
 Lithospermic acid B 565-P
 Live type 1 diabetic patients 1824-P
 Liver 1190-P, 1923-P, 1964-P, 1977-P, 1985-P
 Liver attenuation 2201-P
 Liver enzymes 1227-P
 Liver fat content 1978-P
 Liver function tests 1265-P
 Liver insulin sensitivity 1950-P
 Liver specific 1168-P, 1271-P
 Liver steatosis 2136-P
 Liver transplant patients 114-OR
 Liver transplant 420-P
 Lixisenatide 169-OR, 1113-P, 1145-P, 1147-P, 2565-PO
 LncRNA 133-OR, 1949-P
 Long-acting 100-OR
 Longitudinal health interview survey 1475-P
 Longitudinal study 1494-P, 1599-P
 Longitudinal 1604-P
 Long-term efficacy 1120-P
 Long-term outcome 1721-P
 Loop diuretics 1216-P
 Low birth weight 330-OR, 2079-P
 Low BMI diabetes 1941-P
 Low income setting 2781-PO
 Low pulmonary function in diabetes 2769-PO
 Low-carbohydrate dietary pattern 1627-P
 Low-density lipoprotein cholesterol 2897-PO
 Lower extremity surgical reconstruction 2457-PO
 Lower urinary tract symptoms 635-P, 1592-P
 Low-frequency variants 18-OR
 Low-resource settings 1718-P
 Lung cancer 1697-P
 LY2963016 insulin glargine product 1029-P, 1033-P, 2495-PO
 Lymph node mimicry 1818-P
 Lymphatic absorption 1025-P
 Lymphocytes 1209-P
 Lysyl oxidase 672-P
 M2 macrophages 2244-P
 Machine Learning 962-P, 1523-P, 2429-PO
 Macroalbuminuria 603-P
 Macronutrient intake 2753-PO
 Macrophage 31-OR, 537-P, 1813-P, 1815-P, 1848-P, 1884-P, 2107-P, 2290-P
 Macrophage depression 713-P
 Macrophage infiltration 1166-P
 Macrophage proliferation 336-OR
 Macrosomia 1455-P
 Macrovascular complications 432-P, 1306-P
 Macrovascular events 488-P
 Magnesium levels 2685-PO
 Magnetic resonance and fluoroscopic imaging 1088-P
 Magnetic resonance imaging 192-OR
 Magnetic resonance spectroscopy 1891-P
 Major amputation 1597-P
 Major cardiovascular events 451-P
 Malglycemia 1094-P
 Management 1739-P
 MANF 2277-P
 Manganese 1633-P
 Marine algal polyphenol 2478-PO
 Mast cells 2458-PO, 2705-PO
 Masturbation 2505-PO
 Maternal factors 146-OR
 Maternal inheritance 2847-PO
 Maternal misperceptions 927-P
 Maternal obesity 145-OR
 Maternal weight gain 2675-PO
 Meal frequency 825-P
 Meal replacement 2477-PO
 Mealtime insulin 1649-P
 Meat intake 831-P
 Media communication 904-P
 Medicaid 1673-P
 Medical costs 1327-P, 1357-P
 Medical education 209-OR, 746-P
 Medical expenses 1322-P
 Medical nutritional Therapy 759-P, 775-P
 Medical utilization 261-OR
 Medical-legal partnership 1409-P
 Medicare 1528-P
 Medicare beneficiaries with diabetes 1588-P
 Medicare Part D 264-OR
 Medication adherence 262-OR, 269-OR, 305-OR, 886-P, 889-P, 1335-P, 2503-PO
 Medication utilization 1321-P
 Mediterranean diet 1634-P
 Megalin 590-P
 Menopause 1479-P, 1706-P
 Mental Health 862-P, 1401-P
 Mental well-being 1349-P
 Meta-analysis 860-P, 1030-P, 1127-P, 1258-P
 Metabolic 2783-PO
 Metabolic complications 2217-P
 Metabolic disturbance 2184-P
 Metabolic flexibility 803-P
 Metabolic health 1634-P
 Metabolic healthy obese 2894-PO
 Metabolic Inflexibility 2326-P
 Metabolic memory 683-P
 Metabolic parameters 91-OR
 Metabolic regulation 1973-P
 Metabolic reprogramming 1963-P
 Metabolic risk factors 1534-P
 Metabolic syndrome 484-P, 1565-P, 1719-P, 1916-P, 2132-P, 2231-P, 2241-P, 2482-PO, 2485-PO, 2622-PO, 2646-PO, 2686-PO, 2700-PO, 2712-PO, 2724-PO, 2763-PO, 2846-PO, 2886-PO, 2899-PO, 2921-PO
 Metabolically healthy obese 2222-P, 2819-PO
 Metabolism 376-OR, 2010-P, 2024-P, 2033-P, 2147-P, 2816-PO, 2845-PO
 Metabolite profiling 151-OR
 Metabolites 2065-P
 Metabolomic risk score 75-OR
 Metabolomics 81-OR, 296-OR, 808-P, 1381-P, 1432-P, 1537-P, 1878-P, 2323-P, 2348-P, 2853-PO, 2866-PO
 Metallothionein 3 556-P
 Metformin 9-OR, 649-P, 1180-P, 1182-P, 1207-P, 1224-P, 1237-P, 1282-P, 1295-P, 1313-P, 1636-P, 1690-P, 1822-P, 1830-P, 2409-PO, 2603-PO, 2609-PO, 2856-PO, 2865-PO
 Metformin add-on 1200-P
 Metformin intolerance 1164-P
 Metformin mechanism of action 1181-P
 Methylation 1795-P, 2091-P
 Methylsulfonylmethane 1226-P
 Metoformin 1806-P
 Michigan neuropathy screening instrument 2435-PO
 Microalbuminuria 680-P, 2419-PO, 2689-PO
 Microarray 474-P
 Microbiome 1164-P, 2105-P
 Microbiota 2872-PO
 Microcirculation 1302-P, 1855-P
 Microdosing 2601-PO
 MicroRNA 135-OR, 162-OR, 199-OR, 562-P, 671-P, 1238-P, 1748-P, 1874-P, 1887-P, 2017-P, 2230-P, 2425-PO
 Microvascular complications 661-P, 1595-P, 1617-P
 Microvascular outcomes 14-OR
 Miglitol 1293-P
 Mild hypoglycemia 61-OR, 411-P
 Milk fat 827-P
 Milk proteins 2482-PO
 Mineralocorticoid receptor antagonist 1317-P
 MiR-148a 2188-P
 MiR-200b 461-P
 MiR-204 51-OR
 MiR-26b 1905-P
 MiRNA 37-OR, 338-OR, 526-P, 725-P, 1765-P, 2265-P
 MiRNome 582-P
 Mishaps 863-P
 Misleading blood glucose reading 2530-PO
 Missed-dose 2577-PO
 Mitochondria 82-OR, 370-OR, 375-OR, 377-OR, 681-P, 1875-P, 1886-P, 1893-P, 1920-P, 1935-P, 2019-P, 2026-P, 2829-PO
 Mitochondrial dynamics 2331-P
 Mitochondrial dysfunction 549-P, 2038-P, 2831-PO
 Mitochondrial pyruvate carrier 1879-P
 Mitochondrial uncoupling 1190-P

- Mitochondrial 374-OR, 1786-P
 Mixed meal tolerance test 1931-P
 MMP9 2223-P, 2256-P
 MMTT 1000-P, 2561-PO
 Mobile applications 86-OR, 174-OR, 1405-P
 Mobile health 205-OR, 760-P, 762-P, 902-P, 909-P
 Mobile prescription therapy 909-P
 Mobility loss incidence 1473-P
 Modestly obese blacks and whites 1942-P
 Modified acidic FGF 569-P
 MODY 662-P, 1524-P, 1790-P
 MODY8 2293-P
 Monoacylglycerol acyltransferase 2158-P
 Monocyte 471-P, 1834-P
 Monocytes 2231-P
 Monogenic diabetes 1746-P, 1747-P, 1748-P, 1767-P
 Morbidity 1637-P
 Mortality surveillance 1587-P
 Mortality 16-OR, 152-OR, 273-OR, 720-P, 1355-P, 1474-P, 1507-P, 1514-P, 1664-P, 1675-P, 2246-P, 2776-PO
 Mouse model 1831-P
 MRI 723-P, 1840-P
 MRL mouse strain 2159-P
 MRN complex 2877-PO
 mTOR complex 54-OR, 472-P, 619-P, 1862-P, 1872-P, 1974-P
 Multiethnic 2783-PO
 Muscle 370-OR, 801-P, 2034-P
 Muscle fiber type 2017-P
 Muscle metabolism 319-OR
 Muscle microvascular perfusion 498-P
 Muscle strength 2150-P, 2697-PO
 Muscular strength 2699-PO
 Mutation 1776-P
 Myocardial glucose uptake 78-OR
 Myocardial infarction 55-OR
 Myo-inositol 2373-P
 Myokines 2352-P
 Myosteatosis 2246-P
 NADPH oxidase 2278-P
 Naltrexone bupropion 1287-P
 NASH 1185-P, 1311-P, 1957-P, 2818-PO, 2889-PO
 Native Hawaiian 2914-PO
 Natriuretic peptides 1641-P, 2250-P
 Natural history 358-OR
 Nausea 1152-P
 Nav1.3 2081-P
 Neck circumference 1663-P, 2921-PO
 Neonatal diabetes 1767-P
 Nephlin 83-OR
 Nephropathy 80-OR, 84-OR, 309-OR, 552-P, 555-P, 567-P, 568-P, 572-P, 580-P, 589-P, 598-P, 607-P, 2734-PO
 Nephrylysin 128-OR
 Nephrylysin inhibition 2250-P
 Nerve decompression 1378-P
 Nerve growth factor 2842-PO
 Network meta-analysis 99-OR, 1200-P, 2588-PO, 2602-PO
 Neurocognitive performance 914-P
 Neuroendocrine regulatory peptides 2327-P
 Neuropathy 196-OR, 622-P, 625-P, 627-P, 636-P, 642-P, 647-P, 648-P, 650-P, 651-P, 657-P, 717-P, 2220-P, 2437-PO, 2439-PO, 2443-PO
 Neuropsychological impairments 655-P
 Neutrophil-lymphocyte-ratio 1616-P
 New onset diabetes 2451-PO
 New oral hypoglycemic agent 1233-P
 New therapies 2601-PO
 Newly diagnosed diabetes 1676-P
 Newly diagnosed hyperglycemia 1233-P
 Newly diagnosed type 2 diabetes 1031-P, 1143-P
 Next generation sequencing 1743-P, 1803-P
 NF-kappaB 801-P, 1809-P, 2303-P
 NGS 1790-P
 NHANES 1646-P
 Nicotinic acid 524-P
 Niemann-pickC1-like1 480-P
 Nighttime hypoglycemia 421-P
 Ninety percent pancreatectomy 2286-P
 NIRS 520-P
 Nitrated apolipoprotein AI 254-OR
 Nitric oxide 525-P, 2030-P
 Nitrotyrosine 1999-P
 NLRP3 inflammasome 2211-P, 2415-PO
 NLRP3 2418-PO
 NMES 2624-PO
 NMR lipids 66-OR
 Nocturnal blood pressure dip 457-P
 Nocturnal hypoglycemia 387-P, 1027-P
 Nocturnin 2321-P
 Nod mice 28-OR, 1837-P
 Non-alcoholic fatty liver disease 39-OR, 156-OR, 369-OR, 688-P, 712-P, 1300-P, 1445-P, 1547-P, 1581-P, 1948-P, 2123-P, 2173-P, 2185-P, 2222-P, 2614-PO, 2858-PO
 Non-alcoholic steatohepatitis 2852-PO, 2858-PO, 2867-PO
 Non-diabetic glycemic control 1067-P
 Non-esterified fatty acids 1621-P
 Non-human primate 972-P, 1931-P, 2355-P
 Non-insulin glucose lowering medications 1707-P
 Non-insulin medication 1096-P
 Non-insulin treated 934-P
 Non-invasive tracking 1571-P
 Non-meter glucometer 176-OR
 Non-obese diabetic mouse 2799-PO
 Norepinephrine 3-OR, 2113-P
 Normal weight obesity 2203-P, 2479-PO
 Notch 250-OR
 Novel coding variants 18-OR
 Novel insulin 97-OR
 Novel insulin analog 96-OR
 Novel mutations 1524-P
 Novel therapeutic 1301-P
 Nuclear glucokinase 2320-P
 Nurse perception 774-P
 Nurse 645-P
 Nutrient sensing 2058-P
 Nutrition education 86-OR
 Nutrition therapy 92-OR
 Nutrition 828-P, 1620-P, 1625-P, 2102-P, 2477-PO
 Nutritional status 832-P
 Nutritional supplements 835-P
 Nutritional support 1955-P
 Obesity 79-OR, 161-OR, 162-OR, 334-OR, 838-P, 875-P, 1118-P, 1194-P, 1197-P, 1287-P, 1384-P, 1390-P, 1395-P, 1444-P, 1536-P, 1593-P, 1635-P, 1651-P, 1863-P, 1995-P, 2110-P, 2121-P, 2125-P, 2126-P, 2134-P, 2139-P, 2142-P, 2145-P, 2146-P, 2152-P, 2158-P, 2164-P, 2165-P, 2166-P, 2167-P, 2168-P, 2174-P, 2175-P, 2181-P, 2188-P, 2193-P, 2198-P, 2206-P, 2209-P, 2214-P, 2215-P, 2220-P, 2223-P, 2224-P, 2225-P, 2230-P, 2234-P, 2235-P, 2237-P, 2247-P, 2248-P, 2252-P, 2481-PO, 2529-PO, 2692-PO, 2768-PO, 2872-PO, 2890-PO, 2895-PO, 2903-PO, 2914-PO
 Obstructive sleep apnea 2705-PO
 Occupational health care 2694-PO
 Ocular 685-P
 Offspring adiposity 2750-PO
 Offspring cardio-metabolic risk 145-OR
 O-GlcNAcylation 332-OR, 2273-P
 OGTT 466-P, 2346-P
 Older adults 408-P, 412-P, 1195-P, 1480-P, 1481-P, 1586-P
 Omega-3 fatty acids 836-P, 2009-P
 Omega-3 365-OR
 Onset of disability 1472-P
 Optimal cut-points 1543-P
 Oral agents 1268-P
 Oral antidiabetic therapy 1476-P
 Oral anti-hyperglycemic drug 1686-P
 Oral complications 2046-P
 Oral disposition index 1484-P
 Oral glucose tolerance test 1462-P, 1577-P
 Oral glucose-lowering agents 150-OR
 Oral health related quality of life 1487-P
 Oral health 2737-PO
 Oral hypoglycemic agents 1454-P
 Oral insulin 1058-P
 Oral therapy 1202-P
 Oral tolerance 2799-PO
 Oscillating glucose 533-P
 OSDI score 674-P
 Osteocalcin 1468-P
 Osteomorphic proteins 516-P
 Osteomyelitis 723-P, 733-P
 Osteopontin 646-P
 Out-of-pocket expenditures 262-OR
 Ovariectomy 2135-P
 Overseas born women 788-P
 Overweight 858-P, 1392-P, 1611-P, 2232-P
 Oxidative stress biomarkers 1726-P
 Oxidative stress 546-P, 557-P, 562-P, 570-P, 573-P, 585-P, 618-P, 623-P, 630-P, 811-P, 1448-P, 2264-P, 2743-PO
 Oxymatrine 2036-P, 2040-P
 Oxyntomodulin 2076-P
 Paclitaxel 654-P
 Pain 643-P
 Painful diabetic peripheral neuropathy 2430-PO, 2440-PO
 Pamidronate 2283-P
 Pancreas development 2296-P, 2925-PO
 Pancreas volume 1413-P
 Pancreatectomy 111-OR, 112-OR, 1846-P
 Pancreatic beta cells 249-OR, 2258-P, 2330-P, 2360-P, 2936-PO
 Pancreatic cancer 1765-P
 Pancreatic duct cells 2309-P
 Pancreatic islet 2343-P, 2358-P, 2926-PO
 Pancreatic progenitors 2927-PO
 Pancreatic-derived factor 2056-P
 Pancreatitis 1186-P
 Paracrine effects 2295-P
 Parasympathetic tone 2441-PO
 Parity 1446-P
 Partner support 859-P
 Paternal 1954-P
 Patient barriers 742-P
 Patient characteristics and drug adherence 1285-P, 1707-P
 Patient perspective 756-P
 Patient preference 206-OR, 767-P, 879-P
 Patient response to hypoglycemia 263-OR
 Patient satisfaction 1353-P
 Patient stratification 1717-P
 Patient-centered care 891-P
 Patient-centered outcomes 211-OR, 1330-P, 2655-PO

- Patient-provider communication 908-P
 Patient-provider relationship 885-P
 Patient-reported outcomes 883-P, 1151-P, 1194-P, 2495-PO, 2504-PO
 Pediatric diabetes 2654-PO
 Pediatric screening feasibility 1420-P
 Pediatric type 1 diabetes 1391-P
 Pediatric type 2 diabetes 68-OR
 Pediatrics 64-OR, 357-OR, 976-P, 1060-P, 1403-P, 1421-P, 2647-PO
 Pedometers 809-P
 Peer support 306-OR, 917-P
 PEGylated GLP-1 analogue 275-OR
 Pen 2540-PO
 Peptide hormone 792-P
 Perceived glucose control 1343-P
 Perceived risk 890-P
 Percentage body fat 842-P, 2488-PO
 Perceptions 1041-P
 Pericardial adipose tissue 462-P, 1496-P
 Pericentrin 2932-PO
 Periodontal disease 502-P, 1600-P
 Periodontitis 2801-PO, 2811-PO
 Perioperative glycemic control 1376-P
 Peripheral arterial disease 56-OR, 57-OR, 469-P, 509-P, 1314-P, 2404-PO, 2691-PO
 Peripheral blood gene expression 2247-P
 Peripheral neuropathy 654-P, 2428-PO
 Peripheral serotonin 2087-P
 Peritoneal dialysis 570-P
 Perivascular adipose tissue 453-P, 1855-P
 Perivascular fat 490-P, 553-P
 PERK 51-OR, 2329-P
 Peroxisome proliferator-activated receptors 2148-P
 Peroxynitrite 1999-P
 Persistence 992-P
 Persistent organic pollutants 1386-P, 1575-P
 Personalized A1C goal 1360-P
 Pharmacist 203-OR
 Pharmacodynamics 94-OR, 1022-P, 1133-P, 1174-P
 Pharmacogenetics 1022-P, 1184-P, 1768-P, 1784-P, 2528-PO
 Phosphodiesterase type-5 inhibitor 1585-P
 Phosphoproteomics 320-OR
 Photodynamic therapy 735-P
 Photopharmacology 2357-P
 Photovoice 2656-PO
 Physical activity 496-P, 736-P, 797-P, 822-P, 880-P
 Physician survey 742-P, 1158-P
 Phytochemicals 2245-P
 Phytoestrogens 2135-P
 PI3K 374-OR, 1816-P, 1870-P
 Pima Indians 658-P
 Pin1 2341-P
 Pioglitazone 1297-P, 2065-P, 2614-PO
 PixaTest 176-OR
 Placenta 365-OR, 1423-P, 1455-P, 1459-P, 1465-P
 Plasma amino acid 2098-P
 Plasminogen activator inhibitor 1 2121-P
 Platelet function 353-OR
 Platelets 2062-P
 Pneumococcal vaccination 1700-P
 Podocyte 578-P
 Point-of-care testing 2514-PO
 Polycystic ovary syndrome 2238-P, 2777-PO
 Polyethylene glycol 1839-P
 Polymorphism of interleukin 6 gene 675-P
 Polymorphism 288-OR, 1390-P, 2693-PO
 Polyneuropathy 629-P, 633-P, 645-P
 Polypharmacy 1572-P
 Polyunsaturated fatty acid 467-P, 1989-P
 Pooled cohort equation 1584-P
 Population study 1800-P
 Porcine neonatal pancreatic cell clusters 2927-PO
 Portable pulsimeter 2476-PO
 Portal vein pressure 2623-PO
 Portuguese 2435-PO
 Postpartum 1443-P
 Postpartum glucose test 2673-PO
 Postpartum screening 1450-P
 Post-prandial glucose control 873-P, 907-P, 1374-P
 Post-prandial glycemia 841-P
 Post-prandial glycemic excursion 2520-PO
 Post-prandial hyperglycemia 798-P, 1992-P, 2012-P, 2775-PO
 Post-prandial lipid-metabolism 698-P
 Post-prandial 2001-P
 Posture 727-P
 Potassium 1645-P
 Potential biomarkers 593-P
 PPAR-alpha 550-P, 68-P, 1960-P, 1983-P
 PPAR-gamma 323-OR, 1919-P
 PPARGC1A 2658-PO
 PQI 870-P
 Pramlintide 237-OR, 1159-P, 2555-PO
 Prandial insulin therapy 2539-PO
 Prandial insulin 980-P, 1036-P
 Preadipocyte factor 1 1555-P, 2311-P
 Preadipocyte 1906-P
 Pre-adolescent 845-P
 Preconception counseling 212-OR, 749-P
 Preconception self-care 749-P
 Prediabetes 66-OR, 213-OR, 300-OR, 650-P, 896-P, 950-P, 1382-P, 1545-P, 1546-P, 1558-P, 1561-P, 1570-P, 1673-P, 1679-P, 2739-PO, 2819-PO, 2829-PO, 2876-PO
 Prediabetic state 87-OR, 1562-P
 Prediction model 143-OR, 386-P, 1554-P, 1557-P
 Prediction of diabetes 1529-P
 Prediction of future diabetes 75-OR
 Prediction 1533-P
 Predictive factors 2779-PO
 Predictive model 1365-P, 2428-PO
 Predictors 1034-P, 1046-P, 1145-P, 1685-P, 1724-P, 2568-PO
 Preeclampsia 1464-P
 Pregnancy 664-P, 1073-P, 1432-P, 1438-P, 1451-P, 1466-P, 1468-P, 1471-P, 1620-P, 1778-P, 2672-PO, 2674-PO, 2845-PO, 2930-PO
 Pregnancy nutrition 366-OR
 Pregnancy-induced hypertension 1680-P
 Pregravid obesity 1643-P
 Pre-hospital care 1665-P
 Pre-menopausal bone mineral density 2095-P
 Pre-mixed insulin 2762-PO
 Prenatal vitamins 2750-PO
 Preoperative glycemic control 1352-P, 1373-P
 Preschool 2171-P
 Prescribing patterns 1267-P
 Pre-term birth 2664-PO
 Prevalence of gestational diabetes 71-OR
 Prevalence 270-OR, 1541-P, 1666-P, 1689-P, 2698-PO, 2756-PO
 Prevent hypoglycemia 397-P
 Preventable hospitalizations 1605-P
 Prevention 144-OR, 744-P, 901-P, 2725-PO
 Primary care 210-OR, 745-P, 1324-P, 1336-P, 2635-PO
 PrimaVera study 2892-PO
 Principal components analysis 1462-P
 Prisoners 965-P
 Probabilities of diabetes incidence 1347-P
 ProBNP 1509-P
 Procain 2573-PO
 Prognostic model 445-P
 Pro-inflammatory cytokines 2363-P
 Pro-inflammatory profile 1629-P
 Proinsulin trafficking 2329-P
 Proliferation assay CC401 2291-P
 Proliferation 47-OR
 Prolyl carboxypeptidase 2453-PO
 Prolyl hydroxylase 2330-P
 Prorenin 541-P
 Prospective cohort study of Chinese 1793-P
 Prospective cohort study 1720-P
 Prostate cancer disparity 1636-P
 Protective effect of incretins on the heart 523-P
 Protein biomarkers 1658-P
 Protein C 2405-PO
 Protein kinase A 335-OR
 Protein kinase C 2356-P
 Proteinuria 577-P, 612-P, 1578-P, 1594-P
 Proteome 594-P
 Proteomics 2018-P, 2132-P, 2372-P
 Proton pump inhibitor 2600-PO
 Provider education program 754-P
 Provider type 1329-P
 Psychological counselling 903-P
 Psychological insulin resistance 756-P
 Psychology 901-P
 Psychosocial 928-P
 Psychosocial factors 872-P
 Psychosocial impact 895-P, 2498-PO
 Psychosocial stress 155-OR
 Pubertal development 1643-P
 Public health surveillance 55-OR
 Public health 787-P
 Pulmonary function 1738-P
 Pulse pressure 2399-PO
 Pump 1739-P
 Pyloroplasty 1307-P
 Pyropia yezoensis 2489-PO
 Pyruvate dehydrogenase kinase 2120-P
 QTc interval 2605-PO
 Qualitative 216-OR
 Qualitative research 905-P
 Qualitative study 2510-PO
 Quality 1536-P
 Quality improvement 787-P, 2644-PO
 Quality measurement 1342-P, 1477-P
 Quality of care 1402-P
 Quality of life 657-P, 868-P, 1046-P, 1398-P, 1406-P, 2440-PO
 Quality of outpatient diabetes care 1329-P
 Quantitative sensory testing 1548-P
 Quantitative trait loci 1792-P, 2795-PO
 Questionnaire 501-P, 915-P
 R3hdml 538-P
 Rab proteins 1895-P
 Rab43 2311-P
 Rac1 547-P
 Radiodensity 121-OR
 Ramadan 1121-P
 Random blood glucose 2723-PO
 Randomized clinical trial 1111-P
 Rare variants 1773-P
 RBP4 1860-P, 2881-PO
 Reactive hypoglycemia 1559-P
 Reactive oxygen species 200-OR, 1827-P, 1844-P
 Readmissions 1370-P, 1682-P, 2638-PO
 Real-world effectiveness 992-P, 1220-P
 Rebamipide 1316-P

- Receptor for advanced glycation end products 2261-P, 2264-P
 Receptor signaling 2365-P
 Recombinant human adenoviral-p53 gene 1918-P
 Recovery from mobility loss 1473-P
 Recurrent cardiovascular events 2688-PO
 Red meat 88-OR, 842-P
 Reduced nerve elasticity 634-P
 Reduced renal function 606-P
 Reduction of food intake 2112-P
 REG gene 2369-P
 Regeneration 183-OR, 2284-P, 2302-P
 Regenerative medicine 2814-PO
 Registry 2754-PO
 Regression model 2240-P
 Regulation of insulin secretion 378-OR
 Regulatory T-cells 228-OR, 230-OR, 1804-P, 1821-P, 1823-P, 1829-P
 Regulatory variation 1756-P
 Rehmannia glutinosa 2615-PO
 Reimbursement policy of insulin 2628-PO
 Remission 1056-P, 1685-P
 Remnant cholesterol 499-P
 Remnant lipoprotein 697-P
 Remote therapy 1380-P
 Renal complications 1757-P
 Renal decline 309-OR, 612-P
 Renal denervation 1950-P
 Renal dysfunction 449-P
 Renal fibrosis 554-P, 565-P
 Renal function decline 577-P, 1596-P
 Renal function 1177-P, 1184-P, 1602-P, 2423-PO
 Renal hyperfiltration 610-P
 Renal impairment 270-OR, 595-P
 Renal insufficiency 602-P
 Renal safety during ACS 1281-P
 Renin-angiotensin system 566-P, 2022-P
 Reporting of HbA1c reductions in pooled studies 1277-P
 Reproductive health 207-OR
 Resilience 845-P
 Resistance exercise 793-P
 Resistance training 806-P
 Resistant hypertension 2427-PO
 Resistin 1779-P, 1795-P, 1894-P
 Response 1045-P
 Response to treatment 2575-PO
 Responsibility 866-P
 Restenosis 436-P
 Resveratrol 2743-PO
 Retinal depression sign 286-OR
 Retinal neuroprotection 285-OR
 Retinoids 1857-P
 Retinopathy prediction 683-P
 Retinopathy 662-P, 663-P, 664-P, 666-P, 778-P, 2445-PO
 Retrospective cohort study 14-OR, 2581-PO
 Rhesus monkey 544-P, 2122-P, 2393-PO, 2891-PO
 Rheumatoid arthritis 1646-P, 2839-PO
 Risk assessment 1658-P
 Risk factor control 261-OR
 Risk factor discovery 157-OR
 Risk factor of diabetes in hypertension 2689-PO
 Risk factors 387-P, 392-P, 1558-P, 1695-P, 2459-PO, 2692-PO
 Risk model 1334-P
 Risk of diabetes 153-OR
 Risk of type 2 diabetes 1535-P
 Risk prediction model 157-OR
 Risk prediction 274-OR, 2645-PO
 Risk score 432-P
 RNAi screen 245-OR
 RNA-Seq 194-OR
 ROC AUC 1530-P
 ROS 1814-P, 2418-PO
 Rosiglitazone 329-OR
 Rrbosome 38-OR
 Rwanda 1418-P
 S100 protein 2926-PO
 S20G 2263-P
 Safety 115-OR
 Saliva cortisol 878-P
 Saliva 936-P
 Salivary biomarker 1538-P
 SAP 975-P
 Sarcopenia 2778-PO
 Saroglitazar 693-P, 703-P, 704-P, 1957-P
 Sarpogrelate 560-P
 Satisfaction 915-P
 Saturated fatty acids 1622-P
 Saxagliptin 11-OR, 1209-P, 1212-P, 1227-P, 1228-P, 1232-P, 1248-P, 1264-P, 1270-P, 2606-PO
 Schizophrenia 50-OR
 Sclerostin 500-P
 SCN 2044-P
 Scoring system 1001-P
 Screening 76-OR, 906-P, 922-P, 1531-P, 1540-P, 1546-P, 1570-P, 2679-PO, 2709-PO
 Screening method 739-P
 Screening tools 1545-P
 Second line oral anti-diabetics 2375-PO
 Secretagogues 1171-P
 Secretion 33-OR
 Sedentary behavior 822-P, 1471-P
 Self-care 844-P
 Self-care management 926-P
 Self-efficacy 757-P, 849-P, 1452-P
 Self-management 174-OR, 1642-P, 2494-PO, 2496-PO
 Self-management support 902-P
 Self-monitoring 854-P, 945-P
 Self-monitoring blood glucose 750-P, 763-P, 937-P, 2525-PO, 2526-PO
 Self-tolerance 1818-P
 Senescence 2299-P
 Sensor augmented pump 355-OR, 2519-PO
 Sensor error 417-P
 Sensor glucose alerts 1061-P
 Sensorineural hearing loss 2438-PO
 Septic shock 1615-P
 Sequencing 1791-P
 Serious mental illness 870-P
 Serotonin receptor 1219-P
 Serpin 1810-P, 2139-P
 Serum cystatin C 2741-PO
 Serum ferritin 512-P
 Serum lipids 676-P
 Serum mitochondrial inhibitor 1575-P
 Serum retinol binding protein 1860-P
 Serum uric acid 615-P, 1565-P
 Settings 1131-P
 Severe hypoglycemia 352-OR, 411-P, 2379-PO, 2386-PO
 Sex difference 2716-PO
 Sex steroid 1655-P, 1670-P
 Sexual dysfunction 2738-PO
 SFRP 3 2876-PO
 SFRP4 2353-P
 SGK1 2836-PO
 SGLT inhibitors 2073-P
 SGLT1 knock-out 2517-PO
 SGLT1 transporter inhibitor 2610-PO
 SGLT2 clinical outcomes 1337-P
 SGLT2 inhibitor 105-OR, 107-OR, 543-P, 605-P, 932-P, 948-P, 1172-P, 1173-P, 1177-P, 1197-P, 1198-P, 1210-P, 1215-P, 1217-P, 1223-P, 1225-P, 1229-P, 1235-P, 1236-P, 1255-P, 1274-P, 1276-P, 1303-P, 1396-P, 1907-P, 2307-P, 2340-P, 2582-PO, 2585-PO, 2610-PO, 2616-PO, 2867-PO
 Shared medical appointments 928-P
 Shared transcriptional network 189-OR
 SHBG 1655-P, 1670-P, 2837-PO
 SHBG-estradiol combination 1535-P
 Short acting GLP-1 receptor agonists 1115-P
 Short sleep duration and physical inactivity 858-P
 Short-term glycemia 2514-PO
 Sibutramine 2892-PO
 Sick days 2657-PO
 Sickle cell trait 1525-P
 SIF 1412-P
 Signaling response 1113-P
 Silent type 1 diabetes 359-OR
 Simple CSII 1346-P
 Simulation fixed dose combination 2592-PO
 Single nucleotide polymorphism 477-P, 1794-P
 Single-cell RNA-Seq 2925-PO
 Single-nucleotide polymorphisms 1751-P
 SIRT1 190-OR, 525-P, 1908-P, 2005-P
 Sirtuin 2849-PO
 Sitagliptin 590-P, 697-P, 1290-P, 2450-PO, 2589-PO, 2596-PO, 2621-PO
 Skeletal muscle 43-OR, 372-OR, 376-OR, 816-P, 1881-P, 2020-P, 2024-P, 2028-P, 2033-P
 Skeletal muscle insulin resistance 297-OR
 Skeletal muscle metabolism 371-OR
 Skeletal muscle microvasculature 2030-P
 Skeletal muscle mitochondria 802-P
 Skeletal muscle satellite cells 2035-P
 Skilled nursing facility 1485-P
 Skin advanced glycation end products 1566-P
 Skin autofluorescence 488-P, 503-P, 678-P
 Skin fluorescence 1742-P
 Skinfold thickness 833-P
 SKIP 346-OR
 Sleep 1648-P
 Sleep apnea syndrome 177-OR, 1687-P, 2864-PO
 Sleep disorder 865-P
 Sleep disturbances 877-P
 Sleep duration 1503-P
 Sleep quality 911-P
 Smad 227-OR
 Small for gestational age 2669-PO
 Small molecule 47-OR, 2257-P
 Small RNA 2055-P
 Smartphone application 2225-P
 SMBG 923-P, 973-P
 Smoking cessation 864-P
 Smoking 1710-P, 2711-PO
 SNP 1772-P, 1782-P
 Social media 211-OR, 2496-PO, 2651-PO
 Social network analysis 1672-P
 Social network and behavior modification 875-P
 Social networking 2656-PO
 Social support 905-P
 Socioeconomic factors 1653-P
 Socioeconomic status 874-P
 Sodium-glucose co-transporter 2 522-P, 1178-P, 1203-P, 1285-P, 1292-P
 Soluble RAGE 63-OR, 813-P
 South Asians 1644-P, 1736-P
 Sparse coding 1571-P
 Sphingosine 1-phosphate 36-OR
 Spouse 77-OR

- Sprint exercise 790-P
 Stable incidence 1732-P
 Stair exercise 798-P
 Standardized mortality ratios 1729-P
 Starvation 1980-P
 Statin 433-P, 1550-P
 Statin therapy 1488-P
 Statins 1199-P
 Steatohepatitis 1297-P
 Stem cell educator 1102-P
 Stem cells 233-OR, 246-OR, 284-OR, 721-P, 2144-P
 Steroid diabetes 1001-P
 Stimulus secretion coupling 2323-P
 Streptozotocin induced diabetes 2048-P
 Stress hyperglycemia 587-P
 Stress 850-P, 924-P, 2102-P
 Stroke 478-P, 1502-P, 1503-P
 Structural model 2700-PO
 Structure function relationship 315-OR
 STZ 183-OR
 Subclinical atherosclerosis 508-P, 511-P, 2203-P
 Subclinical coronary atherosclerosis 483-P
 Subclinical Cushing's Syndrome 1564-P
 Subclinical inflammation 1622-P
 Subcutaneous absorption 980-P
 Subjective well-being 2492-PO, 2493-PO
 Subsequent treatment after ITT 1163-P
 Substance use 1702-P
 Substrate oxidation in skeletal muscle 2021-P
 Subtypes of diabetes 1492-P
 Sucralose 2199-P
 Sudden death 349-OR
 Sudomotor dysfunction 644-P
 Sugar sweetened beverages 1628-P, 2006-P
 SUIT 1050-P
 Sulfonylurea 16-OR, 504-P, 1369-P, 2357-P, 2387-PO, 2604-PO
 Superoxide dismutase activity 2824-PO
 Support 2493-PO
 Support programs 767-P
 Supramammillary nucleus 1958-P, 1998-P, 2094-P
 SUR1 17-OR
 Surgical outcome 1008-P
 Survival 2404-PO, 2774-PO
 Survival analysis 1728-P
 Survival and function 132-OR
 Sweat 2437-PO
 Sweet taste receptor 53-OR, 2127-P
 Sympathetic hyperactivity 2228-P
 Syntaxin 2078-P
 Systematic review 2616-PO
 System-wide alert to prevent hypoglycemia 397-P
 Systolic blood pressure variability 1597-P
 Taiwan 2718-PO
 Tanzeum™ 1138-P
 Target organ damage 1520-P
 Target values 1521-P
 Taste receptor 1867-P
 Taurine 2392-PO
 TAZ modulator 1914-P
 TCA cycle 2021-P
 T-cell 27-OR, 29-OR, 234-OR, 1819-P, 1835-P
 Tear osmolarity 2446-PO
 Technology 898-P
 Teen pregnancy 2680-PO
 Telemedicine 734-P, 743-P, 779-P, 1333-P, 1400-P, 1433-P, 2232-P, 2448-PO, 2518-PO, 2522-PO, 2525-PO
 Telenursing glucose measurements 1367-P
 Telmisartan 1701-P
 Tenepliglitin 1251-P
 Testosterone 1512-P, 2733-PO
 Texting mHealth 889-P
 Text-mining of EHRs 1717-P
 TGF-beta 538-P, 2333-P
 TGR5 1186-P
 Therapeutic target 1299-P
 Therapeutics 1997-P
 Therapy 1831-P
 Thermogenesis 337-OR, 338-OR, 2143-P
 Thermogenic capacity 2179-P
 Thermoregulation 2004-P
 Thiodioxin-interacting protein 2366-P
 Thirty-minute postprandial plasma glucose 1638-P
 Threshold suspend 1053-P, 1061-P
 Thyroid 2841-PO
 Thyroid disorders 2455-PO
 Thyroid dysfunctions 1679-P
 Thyroid hormone 959-P, 2362-P, 2371-P
 Tight glycemic control 388-P
 Time preference 864-P
 Tissue inflammation 336-OR
 Tissue transglutaminase antibody 1833-P
 Tissue-specific effect of pioglitazone 194-OR
 Titration algorithm 1037-P
 TNF alpha 1539-P, 1984-P, 2050-P, 2796-PO
 Tobacco cessation 1712-P
 TonEBP 2809-PO
 Total bilirubin 431-P
 Total pancreatectomy 236-OR
 Transcription factor 7-like 2 247-OR, 1439-P, 1441-P, 1761-P, 1798-P, 2304-P, 2812-PO, 2884-PO
 Transcriptome 673-P, 1807-P
 Transcutaneous acupuncture 1304-P
 Transdermal delivery 1065-P
 Transdifferentiation 186-OR
 Transgenic mice 313-OR
 Transition of care 897-P, 1725-P
 Transition to adult care 900-P, 1410-P
 Transition 216-OR, 764-P, 844-P, 848-P, 866-P, 1414-P
 Transplantation 182-OR, 616-P, 1843-P
 Treatment 855-P, 1711-P
 Treatment changes 1315-P
 Treatment intensification 208-OR, 1321-P, 1678-P
 Treatment patterns 1048-P, 2636-PO
 Treatment persistence 884-P
 Tree-structured survival analysis 1493-P
 Trends 1674-P
 Tricyclic compounds 52-OR
 Triglyceride 1769-P, 2870-PO
 Triple-Goal 933-P
 Tropomyosin receptor kinase A 2842-PO
 Tryptophan hydroxylase 2087-P
 Tuberculosis 2800-PO, 2805-PO
 Tubular regeneration 558-P
 Twin pregnancy 2666-PO
 Twin study 426-P
 Type 1 diabetes 6-OR, 70-OR, 80-OR, 201-OR, 218-OR, 219-OR, 221-OR, 226-OR, 229-OR, 230-OR, 237-OR, 271-OR, 277-OR, 279-OR, 308-OR, 342-OR, 355-OR, 358-OR, 361-OR, 405-P, 415-P, 425-P, 445-P, 464-P, 482-P, 519-P, 710-P, 791-P, 808-P, 815-P, 850-P, 861-P, 868-P, 897-P, 899-P, 903-P, 932-P, 941-P, 1051-P, 1063-P, 1068-P, 1074-P, 1093-P, 1102-P, 1159-P, 1170-P, 1213-P, 1295-P, 1353-P, 1401-P, 1404-P, 1407-P, 1410-P, 1414-P, 1416-P, 1417-P, 1421-P, 1493-P, 1495-P, 1613-P, 1619-P, 1625-P, 1731-P, 1732-P, 1733-P, 1734-P, 1735-P, 1740-P, 1741-P, 1745-P, 1750-P, 1753A-P, 1801-P, 1819-P, 1820-P, 2306-P, 2384-PO, 2414-PO, 2483-PO, 2555-PO, 2649-PO, 2786-PO, 2806-PO
 Type 1 diabetes insulin therapy 982-P
 Type 2 diabetes 91-OR, 240-OR, 257-OR, 278-OR, 306-OR, 323-OR, 475-P, 478-P, 487-P, 513-P, 668-P, 687-P, 689-P, 797-P, 853-P, 924-P, 970-P, 995-P, 1006-P, 1007-P, 1010-P, 1026-P, 1049-P, 1062-P, 1097-P, 1100-P, 1260-P, 1263-P, 1266-P, 1273-P, 1282-P, 1379-P, 1383-P, 1392-P, 1486-P, 1490-P, 1511-P, 1521-P, 1560-P, 1585-P, 1623-P, 1627-P, 1633-P, 1648-P, 1654-P, 1698-P, 1708-P, 1711-P, 1715-P, 1755-P, 1768-P, 1773-P, 1775-P, 1777-P, 1781-P, 1800-P, 1825-P, 2023-P, 2038-P, 2054-P, 2198-P, 2214-P, 2226-P, 2398-PO, 2399-PO, 2434-PO, 2439-PO, 2449-PO, 2455-PO, 2520-PO, 2589-PO, 2592-PO, 2607-PO, 2636-PO, 2639-PO, 2641-PO, 2648-PO, 2671-PO, 2735-PO, 2765-PO, 2772-PO, 2773-PO, 2792-PO, 2820-PO, 2824-PO, 2844-PO
 Type 2 diabetes epidemiology 1672-P
 Type 2 diabetes genetics 1771-P
 Type 2 diabetes in pregnancy 1430-P
 Type 2 diabetes mellitus duration 1220-P
 Type 2 diabetic mice 2484-PO
 Ulcer 718-P
 Ultra-rapid insulin 977-P, 979-P, 2531-PO
 Unacylated ghrelin 1097-P
 Uncontrolled diabetes 2576-PO
 Unconventional risk factors 2380-PO
 Unfolded protein response 1960-P
 Unfolded stress response 2332-P
 Urban 1363-P
 Uric acid 579-P, 1608-P
 Urinary incontinence 1599-P, 2730-PO
 Urinary tract infection 1274-P, 2731-PO
 Urine dipstick 2727-PO
 Urine uric acid 615-P
 Urologic complications 1604-P, 1610-P
 Uttarpradesh 2756-PO
 Vagal activation 2074-P
 Vanadium 1716-P
 Variability 1669-P
 Variable dose timing 1018-P
 Various therapies 964-P
 Vascular complications 431-P
 Vascular crosstalk 526-P
 Vascular disease 2696-PO
 Vascular endothelial growth factor 660-P
 Vascular function 2182-P
 Vascular inflammation 462-P
 Vascular insulin resistance 199-OR, 811-P
 Vascular myography 793-P
 Vascular physiology 2066-P
 Vascular recovery 485-P
 Vascular remodeling 529-P
 Vascular smooth muscle cells 197-OR
 Vasculare vents 1509-P, 2697-PO
 Vasonatrin peptide 460-P
 Vasoreactivity 1579-P
 Vegetarian diet 89-OR
 Ventromedial hypothalamus 2113-P
 Vesicles 127-OR
 V-Go 1079-P, 1083-P, 1087-P, 1091-P, 2543-PO, 2546-PO
 Video conferencing 1333-P
 Video games 746-P
 Vildagliptin 942-P, 1283-P, 1978-P, 2609-PO
 Virus 1813-P
 Virus induced diabetes 1817-P, 1827-P
 Visceral adiposity 454-P, 2227-P, 2902-PO

Visceral fat 64-OR, 468-P, 1117-P, 1235-P, 2174-P,
 2221-P, 2897-PO, 2922-PO
 Visfatin 2899-PO
 Vitamin D 487-P, 627-P, 640-P, 838-P, 1416-P,
 1849-P, 2253-P, 2406-PO, 2861-PO
 VLCD 2177-P
 Voice inception 2518-PO
 Waist circumference 1389-P
 Weekly administration 275-OR
 Weekly basal insulin 97-OR
 Weekly insulin 96-OR
 Weight 1034-P, 1134-P, 2569-PO
 Weight change 2178-P
 Weight loss 58-OR, 90-OR, 103-OR, 196-OR,
 291-OR, 840-P, 1133-P, 1631-P, 1651-P, 2192-P,
 2200-P, 2207-P, 2218-P, 2239-P, 2603-PO,
 2887-PO, 2905-PO, 2918-PO
 Weight management 854-P
 Weight regain 2560-PO
 Werner syndrome 1261-P
 Western diet 2164-P
 Whipple triad 1559-P
 White adipose tissue function 2820-PO
 White rice 2486-PO
 Whole exome sequencing 1762-P, 2792-PO
 Whole genome sequencing 17-OR
 Willingness to pay 1341-P, 1344-P
 Wnt pathway 1868-P
 Wnt proteins 840-P
 Wnt signaling 2138-P, 2353-P
 Wolfram syndrome 134-OR, 2269-P
 Worker compensation expenses 2774-PO
 Wound healing 725-P, 2046-P
 Xanthine oxidoreductase 1251-P
 XMetA 1103-P
 Young adult onset diabetes 1744-P
 Young adults 446-P, 2492-PO
 Youth 851-P, 920-P, 1382-P
 ZDF rats 572-P
 Zinc 1617-P
 Zinc transport 1892-P